[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f1aoIAiVypqF8dkOeBDrf6_4PucLHVxpqTe9mhX81BrM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Vertex Pharmaceuticals Incorporated",[4],244,false,32,85,35377,29,5,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Cystic Fibrosis",113,{"name":18,"count":19},"Pain",26,{"name":21,"count":22},"Hepatitis C",18,{"name":24,"count":25},"Acute Pain",10,{"name":27,"count":28},"Hemoglobinopathies",6,{"name":30,"count":28},"Rheumatoid Arthritis",{"name":32,"count":28},"Chronic Hepatitis C",{"name":34,"count":12},"Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[36,41,46,51,54,59,64,69,74,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05668741","A Phase 1\u002F2 Study of VX-522 in Participants With Cystic Fibrosis (CF)","2026-04-21","VX-522 mRNA therapy",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05791201","A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes","2026-05-29","VX-264",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05356195","Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)","2026-05-31","CTX001",{"nctId":52,"briefTitle":53,"date":49,"intervention":50},"NCT05329649","Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT07570069","Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants","2026-07-11","Suzetrigine",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06154447","Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis","2026-07-16","VX-828",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06832410","An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant","2026-09-17","Biological\u002FVaccine",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT05444257","A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy","2026-10-30","VX-121\u002FTEZ\u002FD-IVA",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT07283770","Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants","2026-11-19","VX-581",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06185764","A Phase 1\u002F2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)","2026-12-22","VX-670",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,238,309,738,791,824,869,976,1027,1073,1103,1125,1152,1181,1277,1330,1353,1373,1391,1463,1501,1526,1553,1580,1598,1622,1641,1659,1677,1695,1896,1979,2009,2075,2138,2176,2239,2301,2335,2365,2414,2444,2478,2517,2539,2566,2592,2610,2634,2652,2670,2694,2717,2813,2875,2909,2935,2971,2993,3015,3037,3059,3081,3103,3130,3163,3190,3221,3253,3277,3303,3321,3339,3357,3379,3397,3415,3433,3457,3475,3499,3517,3535,3553,3577,3602,3620,3638,3668,3694,3716,3742,3772,3801,3823,3845,3867,3885,3903,3925,3947,3969,3997,4015,4039,4062,4080,4098,4122,4140,4165,4183,4201,4219,4237,4255,4273,4297,4322,4340,4358,4376,4394,4412,4430,4448,4466,4484,4502,4709,4806,4869,4906,4935],{"intervention":58,"totalTrials":93,"cells":94},13,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":138,"PHASE3":152,"PHASE4":204,"NA":236},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":137,"soonestReadout":57},[100,107,116,126],{"nctId":55,"briefTitle":56,"status":101,"phases":102,"primaryCompletion":57,"completion":57,"start":103,"enrollment":22,"conditions":104,"interventions":105},"RECRUITING",[86],"2026-05-07",[18],[58,106],"Efavirenz",{"nctId":108,"briefTitle":109,"status":101,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":115},"NCT07378865","Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants",[86],"2027-02-26","2026-02-13",12,[18],[58],{"nctId":117,"briefTitle":118,"status":119,"phases":120,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":125},"NCT06336096","A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine","COMPLETED",[86],"2024-06-19","2024-03-28",48,[18],[58,58],{"nctId":127,"briefTitle":128,"status":119,"phases":129,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":134},"NCT06820307","Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants",[86],"2025-04-29","2025-02-25",50,[18],[58,135,136],"DRSP\u002FEE","NGM\u002FEE",2,{"trials":139,"activeCount":97},[140],{"nctId":141,"briefTitle":142,"status":119,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":150},"NCT05660538","Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)",[87],"2023-10-12","2023-10-25","2022-12-20",194,[149],"Diabetic Peripheral Neuropathy",[58,151],"Pregabalin",{"trials":153,"activeCount":203,"soonestReadout":189},[154,163,173,184,194],{"nctId":155,"briefTitle":156,"status":119,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":162},"NCT05661734","A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain",[88],"2023-12-12","2023-01-09",258,[18],[58],{"nctId":164,"briefTitle":165,"status":101,"phases":166,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":172},"NCT06628908","Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy",[88],"2027-05-31","2024-10-01",1100,[171],"Diabetic Peripheral Neuropathic Pain",[58,151],{"nctId":174,"briefTitle":175,"status":119,"phases":176,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":182},"NCT05558410","Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty",[88],"2023-08-25","2023-09-11","2022-10-10",1118,[24],[58,183],"HB\u002FAPAP",{"nctId":185,"briefTitle":186,"status":187,"phases":188,"primaryCompletion":189,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":193},"NCT06696443","Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)","ACTIVE_NOT_RECRUITING",[88],"2027-01-25","2024-12-18",455,[171],[58],{"nctId":195,"briefTitle":196,"status":101,"phases":197,"primaryCompletion":198,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":202},"NCT07231419","Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy",[88],"2027-04-06","2025-11-21",734,[171],[58],3,{"trials":205,"activeCount":235,"soonestReadout":220},[206,216,225],{"nctId":207,"briefTitle":208,"status":119,"phases":209,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":215},"NCT06887959","A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries",[89],"2025-10-27","2025-11-10","2025-03-27",47,[24],[58],{"nctId":217,"briefTitle":218,"status":101,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":224},"NCT07538570","Evaluation of Pain Treatment After Total Knee Arthroplasty",[89],"2027-01-30","2026-04-24",60,[18],[58],{"nctId":226,"briefTitle":227,"status":119,"phases":228,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":234},"NCT06887972","A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries",[89],"2025-10-24","2025-11-07","2025-03-21",100,[24],[58],1,{"trials":237,"activeCount":97},[],{"intervention":50,"totalTrials":28,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":305,"NA":307},{"trials":241,"activeCount":97},[],{"trials":243,"activeCount":97},[],{"trials":245,"activeCount":97},[],{"trials":247,"activeCount":304,"soonestReadout":49},[248,258,267,278,289,297],{"nctId":47,"briefTitle":48,"status":187,"phases":249,"primaryCompletion":49,"completion":49,"start":250,"enrollment":251,"conditions":252,"interventions":257},[88],"2022-05-03",16,[253,254,255,256,27],"Beta-Thalassemia","Thalassemia","Genetic Diseases, Inborn","Hematologic Diseases",[50],{"nctId":259,"briefTitle":260,"status":119,"phases":261,"primaryCompletion":262,"completion":262,"start":263,"enrollment":264,"conditions":265,"interventions":266},"NCT03655678","A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia",[87,88],"2025-11-13","2018-09-14",59,[253,254,255,256,27],[50],{"nctId":268,"briefTitle":269,"status":119,"phases":270,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":277},"NCT03745287","A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease",[87,88],"2025-07-07","2018-11-27",63,[275,276,27],"Sickle Cell Disease","Hematological Diseases",[50],{"nctId":279,"briefTitle":280,"status":281,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":288},"NCT04208529","A Long-term Follow-up Study in Participants Who Received CTX001","ENROLLING_BY_INVITATION",[88],"2039-09-30","2021-01-20",160,[253,254,275,256,27,255,287],"Sickle Cell Anemia",[50],{"nctId":290,"briefTitle":291,"status":101,"phases":292,"primaryCompletion":293,"completion":293,"start":294,"enrollment":19,"conditions":295,"interventions":296},"NCT05477563","Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease",[88],"2027-06-09","2022-08-02",[253,254,256,255,27,275,287],[50],{"nctId":52,"briefTitle":53,"status":187,"phases":298,"primaryCompletion":49,"completion":49,"start":299,"enrollment":93,"conditions":300,"interventions":303},[88],"2022-05-02",[275,301,302,27,276],"Hydroxyurea Failure","Hydroxyurea Intolerance",[50],4,{"trials":306,"activeCount":97},[],{"trials":308,"activeCount":97},[],{"intervention":310,"totalTrials":311,"cells":312},"IVA",46,{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":328,"PHASE3":415,"PHASE4":721,"NA":723},{"trials":314,"activeCount":97},[],{"trials":316,"activeCount":97},[317],{"nctId":318,"briefTitle":319,"status":119,"phases":320,"primaryCompletion":321,"completion":321,"start":322,"enrollment":251,"conditions":323,"interventions":324},"NCT03486236","A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor\u002FIvacaftor in Healthy Adult Subjects",[86],"2016-09-14","2016-07-20",[15],[325,326,310,327],"VX-440","TEZ","Matched Placebos",{"trials":329,"activeCount":235,"soonestReadout":39},[330,340,352,362,372,381,391,400,409],{"nctId":331,"briefTitle":332,"status":119,"phases":333,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":338},"NCT02951182","A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis",[87],"2017-08","2016-10",74,[15],[326,310,325,339],"Matched Placebo",{"nctId":341,"briefTitle":342,"status":119,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":348},"NCT03224351","A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis",[87],"2018-02-28","2017-08-08",124,[15],[349,350,310,326,351],"VX-659","TEZ\u002FIVA","VX-561",{"nctId":353,"briefTitle":354,"status":119,"phases":355,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":360},"NCT03912233","A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis",[87],"2019-12-10","2019-04-30",87,[15],[361,326,351,350,310],"VX-121",{"nctId":363,"briefTitle":364,"status":119,"phases":365,"primaryCompletion":366,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":370},"NCT02951195","A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis",[87],"2018-01","2016-11",80,[15],[371,350,310],"VX-152",{"nctId":373,"briefTitle":374,"status":119,"phases":375,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":380},"NCT03768089","Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis",[86,87],"2019-05-03","2018-03-20",115,[15],[361,350,310,361],{"nctId":382,"briefTitle":383,"status":119,"phases":384,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":389},"NCT03227471","A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis",[86,87],"2018-03-27","2017-01-23",225,[15],[310,350,390,339,326,351,390],"VX-445",{"nctId":392,"briefTitle":393,"status":119,"phases":394,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":399},"NCT03911713","A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis",[87],"2020-08-20","2019-04-17",77,[15],[351,310],{"nctId":401,"briefTitle":402,"status":403,"phases":404,"primaryCompletion":334,"completion":334,"start":405,"enrollment":406,"conditions":407,"interventions":408},"NCT02971839","Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations","TERMINATED",[87],"2016-12",11,[15],[351,310],{"nctId":37,"briefTitle":38,"status":187,"phases":410,"primaryCompletion":39,"completion":411,"start":412,"enrollment":19,"conditions":413,"interventions":414},[86,87],"2026-09-09","2023-02-27",[15],[40,310],{"trials":416,"activeCount":137,"soonestReadout":198},[417,428,438,447,456,466,475,484,493,503,511,519,529,537,545,554,564,573,582,591,600,609,616,623,632,642,651,660,669,679,687,696,705,713],{"nctId":418,"briefTitle":419,"status":119,"phases":420,"primaryCompletion":421,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":426},"NCT05033080","A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F\u002FMF)",[88],"2023-05-12","2023-11-21","2021-09-14",435,[15],[73,427,310],"ELX\u002FTEZ\u002FIVA",{"nctId":429,"briefTitle":430,"status":119,"phases":431,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":436},"NCT03525444","A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F\u002FMF)",[88],"2019-04-24","2018-06-15",405,[15],[437,310],"VX-445\u002FTEZ\u002FIVA",{"nctId":439,"briefTitle":440,"status":119,"phases":441,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":446},"NCT04599465","A Study to Assess the Effect of ELX\u002FTEZ\u002FIVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)",[88],"2022-07-14","2021-01-15",69,[15],[427,310],{"nctId":448,"briefTitle":449,"status":119,"phases":450,"primaryCompletion":451,"completion":451,"start":452,"enrollment":453,"conditions":454,"interventions":455},"NCT05274269","Evaluation of Efficacy and Safety of Elexacaftor\u002FTezacaftor\u002FIvacaftor (ELX\u002FTEZ\u002FIVA) in Cystic Fibrosis Subjects Without an F508del Mutation",[88],"2023-07-05","2022-05-09",307,[15],[427,310],{"nctId":457,"briefTitle":458,"status":119,"phases":459,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":464},"NCT03447249","A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F\u002FMF)",[88],"2019-02-05","2018-03-07",385,[15],[465,310],"VX-659\u002FTEZ\u002FIVA",{"nctId":467,"briefTitle":468,"status":119,"phases":469,"primaryCompletion":470,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":474},"NCT04969224","A Study to Evaluate ELX\u002FTEZ\u002FIVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)",[88],"2022-07-26","2021-10-12",82,[15],[427,310],{"nctId":476,"briefTitle":477,"status":119,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":483},"NCT03559062","A Study to Evaluate Efficacy and Safety of TEZ\u002FIVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis",[88],"2018-12-21","2018-05-17",67,[15],[350,310],{"nctId":485,"briefTitle":486,"status":119,"phases":487,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":492},"NCT04353817","A Study Evaluating Efficacy and Safety of Elexacaftor\u002FTezacaftor\u002FIvacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F\u002FMF Genotypes",[88],"2021-05-17","2020-06-19",121,[15],[427,310],{"nctId":494,"briefTitle":495,"status":119,"phases":496,"primaryCompletion":497,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":502},"NCT02565914","A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation",[88],"2019-05","2022-12-05","2015-08",1131,[15],[350,310],{"nctId":504,"briefTitle":505,"status":119,"phases":506,"primaryCompletion":507,"completion":507,"start":508,"enrollment":16,"conditions":509,"interventions":510},"NCT03525548","A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F\u002FF)",[88],"2018-12-28","2018-08-03",[15],[437,350,310],{"nctId":512,"briefTitle":513,"status":119,"phases":514,"primaryCompletion":159,"completion":159,"start":515,"enrollment":516,"conditions":517,"interventions":518},"NCT03525574","A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy",[88],"2018-10-09",507,[15],[427,310],{"nctId":520,"briefTitle":521,"status":119,"phases":522,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":528},"NCT03537651","A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ\u002FIVA in CF Participants With an F508del CFTR Mutation",[88],"2020-10-28","2023-09-29","2018-04-25",130,[15],[350,310],{"nctId":530,"briefTitle":531,"status":119,"phases":532,"primaryCompletion":146,"completion":146,"start":533,"enrollment":534,"conditions":535,"interventions":536},"NCT05111145","A Study Evaluating the Safety of Elexacaftor\u002FTezacaftor\u002FIvacaftor in Participants With Cystic Fibrosis (CF)",[88],"2022-01-14",86,[15],[427,310],{"nctId":538,"briefTitle":539,"status":187,"phases":540,"primaryCompletion":198,"completion":198,"start":541,"enrollment":542,"conditions":543,"interventions":544},"NCT05331183","Study to Evaluate Elexacaftor\u002FTezacaftor\u002FIvacaftor (ELX\u002FTEZ\u002FIVA) Long-term Safety and Efficacy in Subjects Without F508del",[88],"2022-11-23",297,[15],[427,310],{"nctId":546,"briefTitle":547,"status":119,"phases":548,"primaryCompletion":549,"completion":549,"start":550,"enrollment":551,"conditions":552,"interventions":553},"NCT04537793","Evaluation of ELX\u002FTEZ\u002FIVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years",[88],"2022-06-03","2020-11-19",83,[15],[427,310],{"nctId":555,"briefTitle":556,"status":119,"phases":557,"primaryCompletion":558,"completion":559,"start":560,"enrollment":561,"conditions":562,"interventions":563},"NCT03460990","A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F\u002FF)",[88],"2018-09-26","2018-10-08","2018-05-01",116,[15],[465,350,310],{"nctId":565,"briefTitle":566,"status":119,"phases":567,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":572},"NCT03691779","Evaluation of VX 445\u002FTEZ\u002FIVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age",[88],"2020-08-07","2018-10-02",71,[15],[427,310],{"nctId":574,"briefTitle":575,"status":119,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT04362761","A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy",[88],"2022-12-21","2020-05-04",172,[15],[427,310],{"nctId":583,"briefTitle":584,"status":403,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":590},"NCT03447262","A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy",[88],"2020-09-09","2018-07-13",484,[15],[465,310],{"nctId":592,"briefTitle":593,"status":119,"phases":594,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":598,"interventions":599},"NCT05882357","Evaluation of Elexacaftor\u002FTezacaftor\u002FIvacaftor (ELX\u002FTEZ\u002FIVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age",[88],"2025-09-04","2023-06-27",70,[15],[427,310],{"nctId":601,"briefTitle":602,"status":119,"phases":603,"primaryCompletion":604,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":608},"NCT04058353","A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F\u002FG and F\u002FRF Genotypes)",[88],"2020-06-12","2019-08-28",271,[15],[427,310,350],{"nctId":610,"briefTitle":611,"status":403,"phases":612,"primaryCompletion":613,"completion":613,"start":508,"enrollment":22,"conditions":614,"interventions":615},"NCT03633526","Evaluation of VX-659\u002FTEZ\u002FIVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age",[88],"2019-01-18",[15],[465,310],{"nctId":617,"briefTitle":618,"status":119,"phases":619,"primaryCompletion":620,"completion":620,"start":367,"enrollment":551,"conditions":621,"interventions":622},"NCT02953314","A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661\u002FIvacaftor in Pediatric Subjects With Cystic Fibrosis (CF)",[88],"2018-09",[15],[326,350,310],{"nctId":624,"briefTitle":625,"status":119,"phases":626,"primaryCompletion":627,"completion":627,"start":628,"enrollment":629,"conditions":630,"interventions":631},"NCT04545515","A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor\u002FTezacaftor\u002FIvacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F\u002FMF Genotypes",[88],"2023-03-24","2021-01-11",120,[15],[427,310],{"nctId":633,"briefTitle":634,"status":119,"phases":635,"primaryCompletion":636,"completion":636,"start":637,"enrollment":638,"conditions":639,"interventions":640},"NCT03601637","Safety and Pharmacokinetic Study of Lumacaftor\u002FIvacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del",[88],"2021-10-29","2018-09-07",61,[15],[641,310],"LUM",{"nctId":643,"briefTitle":644,"status":119,"phases":645,"primaryCompletion":646,"completion":646,"start":647,"enrollment":648,"conditions":649,"interventions":650},"NCT04183790","Evaluation of Long-term Safety and Efficacy of ELX\u002FTEZ\u002FIVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older",[88],"2024-02-24","2020-02-17",64,[15],[427,310],{"nctId":652,"briefTitle":653,"status":119,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":658,"interventions":659},"NCT02725567","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation",[88],"2022-06-28","2016-06-02",57,[15],[310],{"nctId":661,"briefTitle":662,"status":119,"phases":663,"primaryCompletion":664,"completion":664,"start":665,"enrollment":666,"conditions":667,"interventions":668},"NCT04043806","A Study Evaluating the Long-term Safety of VX-445 Combination Therapy",[88],"2022-12-14","2019-08-09",458,[15],[427,310],{"nctId":670,"briefTitle":671,"status":119,"phases":672,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":677,"interventions":678},"NCT05076149","A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F\u002FG) or Residual Function (F\u002FRF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation",[88],"2023-05-18","2023-11-30","2021-10-27",597,[15],[73,427,310],{"nctId":680,"briefTitle":681,"status":119,"phases":682,"primaryCompletion":683,"completion":683,"start":684,"enrollment":570,"conditions":685,"interventions":686},"NCT05153317","Evaluation of Long-term Safety and Efficacy of ELX\u002FTEZ\u002FIVA in Cystic Fibrosis (CF) Participants 2 Years and Older",[88],"2026-01-29","2022-01-17",[15],[427,310],{"nctId":688,"briefTitle":689,"status":119,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":695},"NCT04058366","Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy",[88],"2022-12-16","2019-12-05",251,[15],[427,310],{"nctId":697,"briefTitle":698,"status":119,"phases":699,"primaryCompletion":700,"completion":700,"start":701,"enrollment":702,"conditions":703,"interventions":704},"NCT04105972","A Study Evaluating the Efficacy and Safety of VX-445\u002FTezacaftor\u002FIvacaftor in Cystic Fibrosis Subjects, Homozygous for F508del",[88],"2020-07-24","2019-10-03",176,[15],[427,350,310],{"nctId":706,"briefTitle":707,"status":187,"phases":708,"primaryCompletion":709,"completion":709,"start":710,"enrollment":132,"conditions":711,"interventions":712},"NCT06460506","Evaluation of Long-term Safety and Efficacy of ELX\u002FTEZ\u002FIVA in Cystic Fibrosis Participants 12 Months of Age and Older",[88],"2027-09-30","2024-11-21",[15],[427,310],{"nctId":714,"briefTitle":715,"status":119,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"enrollment":534,"conditions":719,"interventions":720},"NCT03277196","A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation",[88],"2023-10-02","2017-08-16",[15],[310],{"trials":722,"activeCount":97},[],{"trials":724,"activeCount":97},[725,732],{"nctId":726,"briefTitle":727,"status":728,"phases":729,"conditions":730,"interventions":731},"NCT04058210","VX-445\u002FTEZ\u002FIVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F\u002FMF Genotypes)","APPROVED_FOR_MARKETING",[],[15],[427,310],{"nctId":733,"briefTitle":734,"status":728,"phases":735,"conditions":736,"interventions":737},"NCT04702360","ELX\u002FTEZ\u002FIVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation",[],[15],[427,310],{"intervention":73,"totalTrials":28,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":760,"PHASE3":762,"PHASE4":787,"NA":789},{"trials":741,"activeCount":97},[],{"trials":743,"activeCount":97},[744,752],{"nctId":745,"briefTitle":746,"status":119,"phases":747,"primaryCompletion":748,"completion":748,"start":749,"enrollment":251,"conditions":750,"interventions":751},"NCT05437120","Pharmacokinetics and Safety Assessment of VX-121\u002FTezacaftor\u002FDeutivacaftor in Participants With Moderate Hepatic Impairment",[86],"2023-03-16","2022-07-22",[15],[73],{"nctId":753,"briefTitle":754,"status":119,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":251,"conditions":758,"interventions":759},"NCT05535959","A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121\u002FTezacaftor\u002FDeutivacaftor",[86],"2022-11-09","2022-09-15",[15],[73],{"trials":761,"activeCount":97},[],{"trials":763,"activeCount":137,"soonestReadout":72},[764,773,777,781],{"nctId":765,"briefTitle":766,"status":187,"phases":767,"primaryCompletion":768,"completion":768,"start":769,"enrollment":770,"conditions":771,"interventions":772},"NCT05422222","Evaluation of VX-121\u002FTezacaftor\u002FDeutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age",[88],"2030-06-30","2022-06-21",210,[15],[73],{"nctId":418,"briefTitle":419,"status":119,"phases":774,"primaryCompletion":421,"completion":422,"start":423,"enrollment":424,"conditions":775,"interventions":776},[88],[15],[73,427,310],{"nctId":670,"briefTitle":671,"status":119,"phases":778,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":779,"interventions":780},[88],[15],[73,427,310],{"nctId":70,"briefTitle":71,"status":187,"phases":782,"primaryCompletion":72,"completion":72,"start":783,"enrollment":784,"conditions":785,"interventions":786},[88],"2022-11-08",822,[15],[73],{"trials":788,"activeCount":97},[],{"trials":790,"activeCount":97},[],{"intervention":151,"totalTrials":203,"cells":792},{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":814,"PHASE4":820,"NA":822},{"trials":794,"activeCount":97},[],{"trials":796,"activeCount":97},[],{"trials":798,"activeCount":235,"soonestReadout":807},[799,803],{"nctId":141,"briefTitle":142,"status":119,"phases":800,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":801,"interventions":802},[87],[149],[58,151],{"nctId":804,"briefTitle":805,"status":101,"phases":806,"primaryCompletion":807,"completion":808,"start":809,"enrollment":810,"conditions":811,"interventions":812},"NCT06619860","Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy",[87],"2027-03-25","2027-04-22","2024-10-18",300,[171],[813,151],"VX-993",{"trials":815,"activeCount":235,"soonestReadout":167},[816],{"nctId":164,"briefTitle":165,"status":101,"phases":817,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":818,"interventions":819},[88],[171],[58,151],{"trials":821,"activeCount":97},[],{"trials":823,"activeCount":97},[],{"intervention":825,"totalTrials":203,"cells":826},"Povetacicept",{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":841,"PHASE3":853,"PHASE4":865,"NA":867},{"trials":828,"activeCount":97},[],{"trials":830,"activeCount":97},[831],{"nctId":832,"briefTitle":833,"status":119,"phases":834,"primaryCompletion":835,"completion":835,"start":836,"enrollment":837,"conditions":838,"interventions":840},"NCT07010406","A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations",[86],"2025-08-19","2025-06-06",136,[839],"Healthy Volunteers",[825],{"trials":842,"activeCount":235,"soonestReadout":847},[843],{"nctId":844,"briefTitle":845,"status":101,"phases":846,"primaryCompletion":847,"completion":847,"start":848,"enrollment":849,"conditions":850,"interventions":852},"NCT07501702","A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis",[87],"2029-03-02","2026-05",30,[851],"Myasthenia Gravis, Generalized",[825],{"trials":854,"activeCount":235,"soonestReadout":859},[855],{"nctId":856,"briefTitle":857,"status":101,"phases":858,"primaryCompletion":859,"completion":859,"start":860,"enrollment":702,"conditions":861,"interventions":863},"NCT07204275","Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)",[87,88],"2028-12-29","2025-09-30",[862],"Primary Membranous Nephropathy",[825,864],"Tacrolimus",{"trials":866,"activeCount":97},[],{"trials":868,"activeCount":97},[],{"intervention":427,"totalTrials":870,"cells":871},23,{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":964,"NA":966},{"trials":873,"activeCount":97},[],{"trials":875,"activeCount":97},[],{"trials":877,"activeCount":97},[],{"trials":879,"activeCount":137,"soonestReadout":198},[880,884,888,892,896,900,904,908,912,916,920,924,928,932,936,940,944,948,952,956,960],{"nctId":418,"briefTitle":419,"status":119,"phases":881,"primaryCompletion":421,"completion":422,"start":423,"enrollment":424,"conditions":882,"interventions":883},[88],[15],[73,427,310],{"nctId":439,"briefTitle":440,"status":119,"phases":885,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":886,"interventions":887},[88],[15],[427,310],{"nctId":448,"briefTitle":449,"status":119,"phases":889,"primaryCompletion":451,"completion":451,"start":452,"enrollment":453,"conditions":890,"interventions":891},[88],[15],[427,310],{"nctId":467,"briefTitle":468,"status":119,"phases":893,"primaryCompletion":470,"completion":470,"start":471,"enrollment":472,"conditions":894,"interventions":895},[88],[15],[427,310],{"nctId":485,"briefTitle":486,"status":119,"phases":897,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":898,"interventions":899},[88],[15],[427,310],{"nctId":512,"briefTitle":513,"status":119,"phases":901,"primaryCompletion":159,"completion":159,"start":515,"enrollment":516,"conditions":902,"interventions":903},[88],[15],[427,310],{"nctId":530,"briefTitle":531,"status":119,"phases":905,"primaryCompletion":146,"completion":146,"start":533,"enrollment":534,"conditions":906,"interventions":907},[88],[15],[427,310],{"nctId":538,"briefTitle":539,"status":187,"phases":909,"primaryCompletion":198,"completion":198,"start":541,"enrollment":542,"conditions":910,"interventions":911},[88],[15],[427,310],{"nctId":546,"briefTitle":547,"status":119,"phases":913,"primaryCompletion":549,"completion":549,"start":550,"enrollment":551,"conditions":914,"interventions":915},[88],[15],[427,310],{"nctId":565,"briefTitle":566,"status":119,"phases":917,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":918,"interventions":919},[88],[15],[427,310],{"nctId":574,"briefTitle":575,"status":119,"phases":921,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":922,"interventions":923},[88],[15],[427,310],{"nctId":592,"briefTitle":593,"status":119,"phases":925,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":926,"interventions":927},[88],[15],[427,310],{"nctId":601,"briefTitle":602,"status":119,"phases":929,"primaryCompletion":604,"completion":604,"start":605,"enrollment":606,"conditions":930,"interventions":931},[88],[15],[427,310,350],{"nctId":624,"briefTitle":625,"status":119,"phases":933,"primaryCompletion":627,"completion":627,"start":628,"enrollment":629,"conditions":934,"interventions":935},[88],[15],[427,310],{"nctId":643,"briefTitle":644,"status":119,"phases":937,"primaryCompletion":646,"completion":646,"start":647,"enrollment":648,"conditions":938,"interventions":939},[88],[15],[427,310],{"nctId":661,"briefTitle":662,"status":119,"phases":941,"primaryCompletion":664,"completion":664,"start":665,"enrollment":666,"conditions":942,"interventions":943},[88],[15],[427,310],{"nctId":670,"briefTitle":671,"status":119,"phases":945,"primaryCompletion":673,"completion":674,"start":675,"enrollment":676,"conditions":946,"interventions":947},[88],[15],[73,427,310],{"nctId":680,"briefTitle":681,"status":119,"phases":949,"primaryCompletion":683,"completion":683,"start":684,"enrollment":570,"conditions":950,"interventions":951},[88],[15],[427,310],{"nctId":688,"briefTitle":689,"status":119,"phases":953,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":954,"interventions":955},[88],[15],[427,310],{"nctId":697,"briefTitle":698,"status":119,"phases":957,"primaryCompletion":700,"completion":700,"start":701,"enrollment":702,"conditions":958,"interventions":959},[88],[15],[427,350,310],{"nctId":706,"briefTitle":707,"status":187,"phases":961,"primaryCompletion":709,"completion":709,"start":710,"enrollment":132,"conditions":962,"interventions":963},[88],[15],[427,310],{"trials":965,"activeCount":97},[],{"trials":967,"activeCount":97},[968,972],{"nctId":726,"briefTitle":727,"status":728,"phases":969,"conditions":970,"interventions":971},[],[15],[427,310],{"nctId":733,"briefTitle":734,"status":728,"phases":973,"conditions":974,"interventions":975},[],[15],[427,310],{"intervention":977,"totalTrials":304,"cells":978},"VNZ\u002FTEZ\u002FD-IVA",{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":1010,"PHASE3":1012,"PHASE4":1023,"NA":1025},{"trials":980,"activeCount":97},[],{"trials":982,"activeCount":97},[983,992,1000],{"nctId":984,"briefTitle":985,"status":119,"phases":986,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":990,"interventions":991},"NCT06299709","A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor\u002FTezacaftor\u002FDeutivacaftor(VNZ\u002FTEZ\u002FD-IVA)",[86],"2024-05-23","2024-03-13",34,[15],[977,977],{"nctId":993,"briefTitle":994,"status":119,"phases":995,"primaryCompletion":996,"completion":996,"start":997,"enrollment":25,"conditions":998,"interventions":999},"NCT06299696","A Study of Vanzacaftor\u002FTezacaftor\u002FDeutivacaftor (VNZ\u002FTEZ\u002FD-IVA) in Healthy Adult Panelists",[86],"2024-04-16","2024-03-26",[15],[977],{"nctId":1001,"briefTitle":1002,"status":119,"phases":1003,"primaryCompletion":1004,"completion":1005,"start":1006,"enrollment":22,"conditions":1007,"interventions":1008},"NCT07349394","Effect of Vanzacaftor\u002FTezacaftor\u002FDeutivacaftor (VNZ\u002FTEZ\u002FD-IVA) on the PK of Rosuvastatin in Healthy Participants",[86],"2026-02-28","2026-03-12","2026-01-12",[15],[977,1009],"Rosuvastatin",{"trials":1011,"activeCount":97},[],{"trials":1013,"activeCount":235,"soonestReadout":1018},[1014],{"nctId":1015,"briefTitle":1016,"status":281,"phases":1017,"primaryCompletion":1018,"completion":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1022},"NCT05844449","Evaluation of Long-Term Safety and Efficacy of Vanzacaftor\u002FTezacaftor\u002FDeutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older",[88],"2029-07-30","2023-08-11",174,[15],[977],{"trials":1024,"activeCount":97},[],{"trials":1026,"activeCount":97},[],{"intervention":1028,"totalTrials":203,"cells":1029},"VX-147",{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1044,"PHASE3":1056,"PHASE4":1069,"NA":1071},{"trials":1031,"activeCount":97},[],{"trials":1033,"activeCount":97},[1034],{"nctId":1035,"briefTitle":1036,"status":119,"phases":1037,"primaryCompletion":1038,"completion":1038,"start":1039,"enrollment":1040,"conditions":1041,"interventions":1043},"NCT05955872","A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147",[86],"2023-09-02","2023-07-19",21,[1042],"Focal Segmental Glomerulosclerosis (FSGS)",[1028],{"trials":1045,"activeCount":97},[1046],{"nctId":1047,"briefTitle":1048,"status":119,"phases":1049,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":251,"conditions":1053,"interventions":1055},"NCT04340362","Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis",[87],"2021-11-11","2021-12-09","2020-06-08",[1054],"Glomerulosclerosis, Focal Segmental",[1028],{"trials":1057,"activeCount":235,"soonestReadout":1062},[1058],{"nctId":1059,"briefTitle":1060,"status":101,"phases":1061,"primaryCompletion":1062,"completion":1063,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1068},"NCT05312879","Phase 2\u002F3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease",[87,88],"2028-06-02","2030-05-07","2022-03-30",466,[1067],"Proteinuric Kidney Disease",[1028],{"trials":1070,"activeCount":97},[],{"trials":1072,"activeCount":97},[],{"intervention":1074,"totalTrials":137,"cells":1075},"tacrolimus",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1091,"PHASE3":1093,"PHASE4":1099,"NA":1101},{"trials":1077,"activeCount":97},[],{"trials":1079,"activeCount":97},[1080],{"nctId":1081,"briefTitle":1082,"status":119,"phases":1083,"primaryCompletion":1084,"completion":1084,"start":1085,"enrollment":1086,"conditions":1087,"interventions":1088},"NCT01038167","A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults",[86],"2010-04","2010-01",20,[21],[1089,1089,1090,1090,1074,1074],"telaprevir","cyclosporine",{"trials":1092,"activeCount":97},[],{"trials":1094,"activeCount":235,"soonestReadout":859},[1095],{"nctId":856,"briefTitle":857,"status":101,"phases":1096,"primaryCompletion":859,"completion":859,"start":860,"enrollment":702,"conditions":1097,"interventions":1098},[87,88],[862],[825,864],{"trials":1100,"activeCount":97},[],{"trials":1102,"activeCount":97},[],{"intervention":68,"totalTrials":235,"cells":1104},{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1121,"NA":1123},{"trials":1106,"activeCount":97},[],{"trials":1108,"activeCount":97},[],{"trials":1110,"activeCount":97},[],{"trials":1112,"activeCount":235,"soonestReadout":67},[1113],{"nctId":65,"briefTitle":66,"status":101,"phases":1114,"primaryCompletion":67,"completion":1115,"start":1116,"enrollment":25,"conditions":1117,"interventions":1120},[88],"2027-09-17","2025-03-31",[1118,1119],"Type 1 Diabetes","Kidney Transplant",[68],{"trials":1122,"activeCount":97},[],{"trials":1124,"activeCount":97},[],{"intervention":1126,"totalTrials":235,"cells":1127},"VX-880",{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1134,"PHASE4":1148,"NA":1150},{"trials":1129,"activeCount":97},[],{"trials":1131,"activeCount":97},[],{"trials":1133,"activeCount":97},[],{"trials":1135,"activeCount":235,"soonestReadout":1140},[1136],{"nctId":1137,"briefTitle":1138,"status":101,"phases":1139,"primaryCompletion":1140,"completion":768,"start":1141,"enrollment":1142,"conditions":1143,"interventions":1147},"NCT04786262","A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes",[88],"2027-06-30","2021-03-29",52,[1144,1145,1146],"Diabetes Mellitus, Type 1","Impaired Hypoglycemic Awareness","Severe Hypoglycemia",[1126],{"trials":1149,"activeCount":97},[],{"trials":1151,"activeCount":97},[],{"intervention":83,"totalTrials":137,"cells":1153},{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1155,"activeCount":97},[],{"trials":1157,"activeCount":97},[],{"trials":1159,"activeCount":137,"soonestReadout":82},[1160,1167],{"nctId":80,"briefTitle":81,"status":101,"phases":1161,"primaryCompletion":82,"completion":82,"start":1162,"enrollment":1163,"conditions":1164,"interventions":1166},[86,87],"2024-02-20",44,[1165],"Myotonic Dystrophy Type 1 (DM1)",[83],{"nctId":1168,"briefTitle":1169,"status":281,"phases":1170,"primaryCompletion":1171,"completion":1171,"start":1172,"enrollment":1163,"conditions":1173,"interventions":1174},"NCT06926621","A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I",[87],"2029-01-30","2025-04-28",[1165],[83],{"trials":1176,"activeCount":97},[],{"trials":1178,"activeCount":97},[],{"trials":1180,"activeCount":97},[],{"intervention":813,"totalTrials":1182,"cells":1183},9,{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1256,"PHASE3":1271,"PHASE4":1273,"NA":1275},{"trials":1185,"activeCount":97},[],{"trials":1187,"activeCount":97},[1188,1195,1204,1216,1225,1235,1244],{"nctId":1189,"briefTitle":1190,"status":119,"phases":1191,"primaryCompletion":1192,"completion":1192,"start":664,"enrollment":597,"conditions":1193,"interventions":1194},"NCT05653323","A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants",[86],"2023-09-12",[18],[813],{"nctId":1196,"briefTitle":1197,"status":119,"phases":1198,"primaryCompletion":1199,"completion":1199,"start":1200,"enrollment":1201,"conditions":1202,"interventions":1203},"NCT06508762","A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993",[86],"2024-09-10","2024-07-26",24,[18],[813],{"nctId":1205,"briefTitle":1206,"status":119,"phases":1207,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":1210,"conditions":1211,"interventions":1212},"NCT06392659","A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults",[86],"2024-07-02","2024-05-02",42,[18],[813,1213,1214,1215],"Gemfibrozil","Itraconazole","Midazolam",{"nctId":1217,"briefTitle":1218,"status":119,"phases":1219,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":1222,"conditions":1223,"interventions":1224},"NCT06394167","A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults",[86],"2025-02-18","2024-05-09",88,[18],[813],{"nctId":1226,"briefTitle":1227,"status":119,"phases":1228,"primaryCompletion":1229,"completion":1229,"start":1230,"enrollment":1231,"conditions":1232,"interventions":1233},"NCT06523595","Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults",[86],"2024-12-31","2024-07-31",31,[18],[813,1234],"Metformin",{"nctId":1236,"briefTitle":1237,"status":119,"phases":1238,"primaryCompletion":1239,"completion":1239,"start":1240,"enrollment":1241,"conditions":1242,"interventions":1243},"NCT06226454","A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993",[86],"2024-06-12","2024-01-04",39,[18],[813],{"nctId":1245,"briefTitle":1246,"status":119,"phases":1247,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":1251,"conditions":1252,"interventions":1253},"NCT06420765","A Microneurography Study of NaV1.8 Inhibition in Healthy Adults",[86],"2025-03-22","2025-04-04","2024-05-21",92,[18],[1254,1255,813],"VX-150","VX-548",{"trials":1257,"activeCount":235,"soonestReadout":807},[1258,1267],{"nctId":1259,"briefTitle":1260,"status":119,"phases":1261,"primaryCompletion":1262,"completion":1262,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1266},"NCT06619847","A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy",[87],"2025-05-27","2024-10-29",367,[24],[813,183],{"nctId":804,"briefTitle":805,"status":101,"phases":1268,"primaryCompletion":807,"completion":808,"start":809,"enrollment":810,"conditions":1269,"interventions":1270},[87],[171],[813,151],{"trials":1272,"activeCount":97},[],{"trials":1274,"activeCount":97},[],{"trials":1276,"activeCount":97},[],{"intervention":1278,"totalTrials":304,"cells":1279},"VX-407",{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1313,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1281,"activeCount":97},[],{"trials":1283,"activeCount":97},[1284,1292,1303],{"nctId":1285,"briefTitle":1286,"status":119,"phases":1287,"primaryCompletion":1288,"completion":1288,"start":1289,"enrollment":8,"conditions":1290,"interventions":1291},"NCT07022119","A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants",[86],"2026-02-24","2025-06-12",[34],[1278],{"nctId":1293,"briefTitle":1294,"status":119,"phases":1295,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":336,"conditions":1299,"interventions":1300},"NCT07074327","Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants",[86],"2026-02-20","2026-02-27","2025-07-11",[34],[1278,1301,136,1302,135],"LNG\u002FEE","NET\u002FEE",{"nctId":1304,"briefTitle":1305,"status":119,"phases":1306,"primaryCompletion":1307,"completion":1308,"start":1309,"enrollment":1310,"conditions":1311,"interventions":1312},"NCT06345755","A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants",[86],"2025-01-27","2025-06-13","2024-04-17",159,[34],[1278,1215,1278],{"trials":1314,"activeCount":235,"soonestReadout":1319},[1315],{"nctId":1316,"briefTitle":1317,"status":101,"phases":1318,"primaryCompletion":1319,"completion":1320,"start":1321,"enrollment":1201,"conditions":1322,"interventions":1323},"NCT07161037","Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)",[87],"2027-07-22","2027-12-31","2025-11-19",[34],[1278],{"trials":1325,"activeCount":97},[],{"trials":1327,"activeCount":97},[],{"trials":1329,"activeCount":97},[],{"intervention":1331,"totalTrials":235,"cells":1332},"Inaxaplin",{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1337,"PHASE3":1347,"PHASE4":1349,"NA":1351},{"trials":1334,"activeCount":97},[],{"trials":1336,"activeCount":97},[],{"trials":1338,"activeCount":235,"soonestReadout":1343},[1339],{"nctId":1340,"briefTitle":1341,"status":187,"phases":1342,"primaryCompletion":1343,"completion":1343,"start":1344,"enrollment":1210,"conditions":1345,"interventions":1346},"NCT06794996","Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities",[87],"2026-12-30","2025-02-04",[1067],[1331],{"trials":1348,"activeCount":97},[],{"trials":1350,"activeCount":97},[],{"trials":1352,"activeCount":97},[],{"intervention":45,"totalTrials":235,"cells":1354},{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1367,"PHASE4":1369,"NA":1371},{"trials":1356,"activeCount":97},[],{"trials":1358,"activeCount":97},[],{"trials":1360,"activeCount":235,"soonestReadout":44},[1361],{"nctId":42,"briefTitle":43,"status":187,"phases":1362,"primaryCompletion":44,"completion":44,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1366},[86,87],"2023-05-16",7,[1118],[45],{"trials":1368,"activeCount":97},[],{"trials":1370,"activeCount":97},[],{"trials":1372,"activeCount":97},[],{"intervention":40,"totalTrials":235,"cells":1374},{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1379,"PHASE3":1385,"PHASE4":1387,"NA":1389},{"trials":1376,"activeCount":97},[],{"trials":1378,"activeCount":97},[],{"trials":1380,"activeCount":235,"soonestReadout":39},[1381],{"nctId":37,"briefTitle":38,"status":187,"phases":1382,"primaryCompletion":39,"completion":411,"start":412,"enrollment":19,"conditions":1383,"interventions":1384},[86,87],[15],[40,310],{"trials":1386,"activeCount":97},[],{"trials":1388,"activeCount":97},[],{"trials":1390,"activeCount":97},[],{"intervention":1215,"totalTrials":1364,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1455,"PHASE3":1457,"PHASE4":1459,"NA":1461},{"trials":1394,"activeCount":97},[],{"trials":1396,"activeCount":137,"soonestReadout":62},[1397,1406,1415,1419,1430,1443,1451],{"nctId":1398,"briefTitle":1399,"status":119,"phases":1400,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":648,"conditions":1403,"interventions":1404},"NCT05518734","A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants",[86],"2023-03-07","2022-09-17",[18],[1405,1214,1215],"VX-708",{"nctId":1407,"briefTitle":1408,"status":119,"phases":1409,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":849,"conditions":1412,"interventions":1413},"NCT05866055","A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults",[86],"2024-04-04","2023-05-10",[18],[1414,1215],"VX-973",{"nctId":1205,"briefTitle":1206,"status":119,"phases":1416,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":1210,"conditions":1417,"interventions":1418},[86],[18],[813,1213,1214,1215],{"nctId":1420,"briefTitle":1421,"status":119,"phases":1422,"primaryCompletion":1423,"completion":1424,"start":1425,"enrollment":1426,"conditions":1427,"interventions":1428},"NCT05541471","A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin",[86],"2023-04-16","2023-04-28","2022-09-22",37,[18],[1255,1215,1429],"Digoxin",{"nctId":1431,"briefTitle":1432,"status":1433,"phases":1434,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":1437,"conditions":1438,"interventions":1440},"NCT07584434","A Phase 1, First-in-human Study of VX-433","NOT_YET_RECRUITING",[86],"2027-03-05","2026-05-12",118,[1439],"Narcolepsy Type 1 (NT1)",[1441,1215,1442],"VX-433","Bupropion",{"nctId":60,"briefTitle":61,"status":187,"phases":1444,"primaryCompletion":62,"completion":62,"start":158,"enrollment":1445,"conditions":1446,"interventions":1447},[86],165,[15],[63,1214,1215,1448,1449,1450,63],"Tezacaftor","VX-118","Deutivacaftor",{"nctId":1304,"briefTitle":1305,"status":119,"phases":1452,"primaryCompletion":1307,"completion":1308,"start":1309,"enrollment":1310,"conditions":1453,"interventions":1454},[86],[34],[1278,1215,1278],{"trials":1456,"activeCount":97},[],{"trials":1458,"activeCount":97},[],{"trials":1460,"activeCount":97},[],{"trials":1462,"activeCount":97},[],{"intervention":1214,"totalTrials":304,"cells":1464},{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1493,"PHASE3":1495,"PHASE4":1497,"NA":1499},{"trials":1466,"activeCount":97},[],{"trials":1468,"activeCount":235,"soonestReadout":62},[1469,1481,1485,1489],{"nctId":1470,"briefTitle":1471,"status":119,"phases":1472,"primaryCompletion":1473,"start":1474,"enrollment":368,"conditions":1475,"interventions":1476},"NCT01768663","A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects",[86],"2013-09","2013-01",[15],[1477,1478,1479,1214,1480],"Lumacaftor","Ivacaftor","Ciprofloxacin","Rifampin",{"nctId":1398,"briefTitle":1399,"status":119,"phases":1482,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":648,"conditions":1483,"interventions":1484},[86],[18],[1405,1214,1215],{"nctId":1205,"briefTitle":1206,"status":119,"phases":1486,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":1210,"conditions":1487,"interventions":1488},[86],[18],[813,1213,1214,1215],{"nctId":60,"briefTitle":61,"status":187,"phases":1490,"primaryCompletion":62,"completion":62,"start":158,"enrollment":1445,"conditions":1491,"interventions":1492},[86],[15],[63,1214,1215,1448,1449,1450,63],{"trials":1494,"activeCount":97},[],{"trials":1496,"activeCount":97},[],{"trials":1498,"activeCount":97},[],{"trials":1500,"activeCount":97},[],{"intervention":1448,"totalTrials":137,"cells":1502},{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1518,"PHASE3":1520,"PHASE4":1522,"NA":1524},{"trials":1504,"activeCount":97},[],{"trials":1506,"activeCount":235,"soonestReadout":62},[1507,1514],{"nctId":1508,"briefTitle":1509,"status":119,"phases":1510,"primaryCompletion":334,"completion":334,"start":367,"enrollment":1511,"conditions":1512,"interventions":1513},"NCT03029455","A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis",[86],163,[15],[349,1448,1478],{"nctId":60,"briefTitle":61,"status":187,"phases":1515,"primaryCompletion":62,"completion":62,"start":158,"enrollment":1445,"conditions":1516,"interventions":1517},[86],[15],[63,1214,1215,1448,1449,1450,63],{"trials":1519,"activeCount":97},[],{"trials":1521,"activeCount":97},[],{"trials":1523,"activeCount":97},[],{"trials":1525,"activeCount":97},[],{"intervention":63,"totalTrials":137,"cells":1527},{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1545,"PHASE3":1547,"PHASE4":1549,"NA":1551},{"trials":1529,"activeCount":97},[],{"trials":1531,"activeCount":235,"soonestReadout":62},[1532,1541],{"nctId":1533,"briefTitle":1534,"status":119,"phases":1535,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":1538,"conditions":1539,"interventions":1540},"NCT06861413","A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation",[86],"2025-05-05","2025-04-01",68,[15],[63,63],{"nctId":60,"briefTitle":61,"status":187,"phases":1542,"primaryCompletion":62,"completion":62,"start":158,"enrollment":1445,"conditions":1543,"interventions":1544},[86],[15],[63,1214,1215,1448,1449,1450,63],{"trials":1546,"activeCount":97},[],{"trials":1548,"activeCount":97},[],{"trials":1550,"activeCount":97},[],{"trials":1552,"activeCount":97},[],{"intervention":1449,"totalTrials":137,"cells":1554},{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1572,"PHASE3":1574,"PHASE4":1576,"NA":1578},{"trials":1556,"activeCount":97},[],{"trials":1558,"activeCount":235,"soonestReadout":62},[1559,1568],{"nctId":1560,"briefTitle":1561,"status":119,"phases":1562,"primaryCompletion":1563,"completion":1563,"start":1564,"enrollment":1565,"conditions":1566,"interventions":1567},"NCT06312787","A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation",[86],"2024-05-04","2024-04-02",15,[15],[1449],{"nctId":60,"briefTitle":61,"status":187,"phases":1569,"primaryCompletion":62,"completion":62,"start":158,"enrollment":1445,"conditions":1570,"interventions":1571},[86],[15],[63,1214,1215,1448,1449,1450,63],{"trials":1573,"activeCount":97},[],{"trials":1575,"activeCount":97},[],{"trials":1577,"activeCount":97},[],{"trials":1579,"activeCount":97},[],{"intervention":106,"totalTrials":235,"cells":1581},{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1590,"PHASE3":1592,"PHASE4":1594,"NA":1596},{"trials":1583,"activeCount":97},[],{"trials":1585,"activeCount":235,"soonestReadout":57},[1586],{"nctId":55,"briefTitle":56,"status":101,"phases":1587,"primaryCompletion":57,"completion":57,"start":103,"enrollment":22,"conditions":1588,"interventions":1589},[86],[18],[58,106],{"trials":1591,"activeCount":97},[],{"trials":1593,"activeCount":97},[],{"trials":1595,"activeCount":97},[],{"trials":1597,"activeCount":97},[],{"intervention":1599,"totalTrials":235,"cells":1600},"VX-272",{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1614,"PHASE3":1616,"PHASE4":1618,"NA":1620},{"trials":1602,"activeCount":97},[],{"trials":1604,"activeCount":235,"soonestReadout":1609},[1605],{"nctId":1606,"briefTitle":1607,"status":101,"phases":1608,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":1611,"conditions":1612,"interventions":1613},"NCT07437105","Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants",[86],"2027-03-23","2026-02-25",128,[15],[1599],{"trials":1615,"activeCount":97},[],{"trials":1617,"activeCount":97},[],{"trials":1619,"activeCount":97},[],{"trials":1621,"activeCount":97},[],{"intervention":78,"totalTrials":235,"cells":1623},{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1633,"PHASE3":1635,"PHASE4":1637,"NA":1639},{"trials":1625,"activeCount":97},[],{"trials":1627,"activeCount":235,"soonestReadout":77},[1628],{"nctId":75,"briefTitle":76,"status":101,"phases":1629,"primaryCompletion":77,"completion":77,"start":1630,"enrollment":1611,"conditions":1631,"interventions":1632},[86],"2025-12-09",[15],[78],{"trials":1634,"activeCount":97},[],{"trials":1636,"activeCount":97},[],{"trials":1638,"activeCount":97},[],{"trials":1640,"activeCount":97},[],{"intervention":1441,"totalTrials":235,"cells":1642},{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1651,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1644,"activeCount":97},[],{"trials":1646,"activeCount":235,"soonestReadout":1435},[1647],{"nctId":1431,"briefTitle":1432,"status":1433,"phases":1648,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":1437,"conditions":1649,"interventions":1650},[86],[1439],[1441,1215,1442],{"trials":1652,"activeCount":97},[],{"trials":1654,"activeCount":97},[],{"trials":1656,"activeCount":97},[],{"trials":1658,"activeCount":97},[],{"intervention":1442,"totalTrials":235,"cells":1660},{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1669,"PHASE3":1671,"PHASE4":1673,"NA":1675},{"trials":1662,"activeCount":97},[],{"trials":1664,"activeCount":235,"soonestReadout":1435},[1665],{"nctId":1431,"briefTitle":1432,"status":1433,"phases":1666,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":1437,"conditions":1667,"interventions":1668},[86],[1439],[1441,1215,1442],{"trials":1670,"activeCount":97},[],{"trials":1672,"activeCount":97},[],{"trials":1674,"activeCount":97},[],{"trials":1676,"activeCount":97},[],{"intervention":1450,"totalTrials":235,"cells":1678},{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1687,"PHASE3":1689,"PHASE4":1691,"NA":1693},{"trials":1680,"activeCount":97},[],{"trials":1682,"activeCount":235,"soonestReadout":62},[1683],{"nctId":60,"briefTitle":61,"status":187,"phases":1684,"primaryCompletion":62,"completion":62,"start":158,"enrollment":1445,"conditions":1685,"interventions":1686},[86],[15],[63,1214,1215,1448,1449,1450,63],{"trials":1688,"activeCount":97},[],{"trials":1690,"activeCount":97},[],{"trials":1692,"activeCount":97},[],{"trials":1694,"activeCount":97},[],{"intervention":1696,"totalTrials":1697,"cells":1698},"Ribavirin",19,{"EARLY_PHASE1":1699,"PHASE1":1701,"PHASE2":1703,"PHASE3":1844,"PHASE4":1884,"NA":1894},{"trials":1700,"activeCount":97},[],{"trials":1702,"activeCount":97},[],{"trials":1704,"activeCount":97},[1705,1717,1729,1741,1753,1763,1771,1780,1790,1800,1808,1817,1826,1836],{"nctId":1706,"briefTitle":1707,"status":119,"phases":1708,"primaryCompletion":1709,"completion":1710,"start":1711,"enrollment":648,"conditions":1712,"interventions":1714},"NCT01581138","VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C",[87],"2013-06","2013-12","2012-07",[1713],"Chronic Hepatitis C Virus",[1715,1089,1716],"VX-222","ribavirin",{"nctId":1718,"briefTitle":1719,"status":119,"phases":1720,"primaryCompletion":1721,"completion":1722,"start":1723,"enrollment":1724,"conditions":1725,"interventions":1726},"NCT00420784","A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)",[87],"2008-12","2009-04","2007-02",465,[21],[1727,1696,1728],"Telaprevir","Pegylated Interferon Alfa 2a",{"nctId":1730,"briefTitle":1731,"status":403,"phases":1732,"primaryCompletion":1733,"completion":1734,"start":1735,"enrollment":1736,"conditions":1737,"interventions":1739},"NCT01080222","A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection",[87],"2013-10","2013-11","2010-08",152,[1738],"Chronic Hepatitis C Virus Infection",[1089,1715,1716,1740,1715],"peginterferon-alfa-2a",{"nctId":1742,"briefTitle":1743,"status":119,"phases":1744,"completion":1745,"start":1746,"enrollment":1747,"conditions":1748,"interventions":1750},"NCT00088504","Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C",[87],"2006-10","2004-07",315,[21,1749],"Hepatitis",[1751,1752,1696],"Merimepodib","PEG-Interferon-alpha 2a",{"nctId":1754,"briefTitle":1755,"status":119,"phases":1756,"completion":1757,"start":1758,"enrollment":113,"conditions":1759,"interventions":1760},"NCT00262483","Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C",[87],"2006-04","2005-12",[21],[1761,1716,1762],"VX-950","peginterferon alfa-2a",{"nctId":1764,"briefTitle":1765,"status":119,"phases":1766,"primaryCompletion":1473,"completion":1710,"start":1767,"enrollment":1768,"conditions":1769,"interventions":1770},"NCT01516918","A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis",[87],"2012-02",103,[1713],[1715,1089,1716,1740],{"nctId":1772,"briefTitle":1773,"status":119,"phases":1774,"primaryCompletion":1775,"completion":1775,"start":1776,"enrollment":25,"conditions":1777,"interventions":1778},"NCT01726946","A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C",[87],"2014-02","2012-11",[32],[1779,1716],"VX-135",{"nctId":1781,"briefTitle":1782,"status":119,"phases":1783,"primaryCompletion":1784,"completion":1784,"start":1785,"enrollment":1786,"conditions":1787,"interventions":1788},"NCT00535847","A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy",[87],"2010-02","2007-10",117,[21],[1727,1696,1789],"Pegylated interferon alfa 2a",{"nctId":1791,"briefTitle":1792,"status":119,"phases":1793,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1797,"conditions":1798,"interventions":1799},"NCT00372385","Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C",[87],"2008-05","2008-06","2006-08",334,[32],[1696,1728,1727],{"nctId":1801,"briefTitle":1802,"status":403,"phases":1803,"primaryCompletion":1804,"completion":1804,"start":1474,"enrollment":1210,"conditions":1805,"interventions":1806},"NCT01701063","An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus",[86,87],"2015-04",[21],[1727,1807,1696],"Peginterferon alfa-2b",{"nctId":1809,"briefTitle":1810,"status":403,"phases":1811,"primaryCompletion":1812,"completion":1812,"start":1767,"enrollment":638,"conditions":1813,"interventions":1814},"NCT01467505","An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients",[87],"2014-04",[21],[1727,1696,1815,1816],"Pegylated Interferon Alfa-2a","Immunosuppressant Regimen",{"nctId":1818,"briefTitle":1819,"status":119,"phases":1820,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":1823,"conditions":1824,"interventions":1825},"NCT00336479","Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C",[87],"2008-02","2006-06",263,[32],[1727,1696,1728],{"nctId":1827,"briefTitle":1828,"status":119,"phases":1829,"primaryCompletion":1830,"start":1831,"enrollment":1832,"conditions":1833,"interventions":1835},"NCT00983853","Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV",[87],"2012-03","2009-10",62,[21,1834],"HIV Infections",[1762,1716,1716],{"nctId":1837,"briefTitle":1838,"status":119,"phases":1839,"primaryCompletion":1840,"completion":1840,"start":1722,"enrollment":1841,"conditions":1842,"interventions":1843},"NCT00911963","Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection",[86,87],"2012-09",49,[21],[1762,1716],{"trials":1845,"activeCount":97},[1846,1856,1865,1875],{"nctId":1847,"briefTitle":1848,"status":119,"phases":1849,"primaryCompletion":1850,"completion":1851,"start":1852,"enrollment":1853,"conditions":1854,"interventions":1855},"NCT00758043","A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response",[88],"2010-06","2010-07","2008-10",540,[21],[1089,1716,1762],{"nctId":1857,"briefTitle":1858,"status":403,"phases":1859,"primaryCompletion":1775,"completion":1775,"start":1860,"enrollment":1861,"conditions":1862,"interventions":1863},"NCT01467479","A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)",[88],"2011-12",185,[21],[1727,1696,1815,1864],"Highly Active Antiretroviral Therapy",{"nctId":1866,"briefTitle":1867,"status":403,"phases":1868,"primaryCompletion":1869,"completion":1869,"start":1870,"enrollment":1871,"conditions":1872,"interventions":1874},"NCT01459913","Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype",[88],"2014-01","2011-11",239,[1873],"Hepatitis C, Chronic",[1727,1815,1696],{"nctId":1876,"briefTitle":1877,"status":119,"phases":1878,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":1882,"interventions":1883},"NCT00627926","A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)",[88],"2010-05","2008-03",1095,[21],[1728,1727,1696],{"trials":1885,"activeCount":97},[1886],{"nctId":1887,"briefTitle":1888,"status":403,"phases":1889,"primaryCompletion":1890,"completion":1890,"start":1891,"enrollment":490,"conditions":1892,"interventions":1893},"NCT01467492","Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black\u002FAfrican American and Non-Black\u002FAfrican American Subjects With Genotype 1 Chronic Hepatitis C",[89],"2014-05","2012-01",[21],[1727,1696,1815],{"trials":1895,"activeCount":97},[],{"intervention":1897,"totalTrials":1898,"cells":1899},"LUM\u002FIVA",8,{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1925,"PHASE4":1960,"NA":1977},{"trials":1901,"activeCount":97},[],{"trials":1903,"activeCount":97},[],{"trials":1905,"activeCount":97},[1906,1915],{"nctId":1907,"briefTitle":1908,"status":119,"phases":1909,"primaryCompletion":1910,"completion":1911,"start":1912,"enrollment":1086,"conditions":1913,"interventions":1914},"NCT03061331","Lumacaftor\u002FIvacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation",[87],"2017-09-06","2017-10-04","2017-01-31",[15],[1897],{"nctId":1916,"briefTitle":1917,"status":119,"phases":1918,"primaryCompletion":1919,"completion":1920,"start":1921,"enrollment":1922,"conditions":1923,"interventions":1924},"NCT03625466","A Study to Explore the Impact of Lumacaftor\u002FIvacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del",[87],"2020-10-09","2021-10-07","2018-08-10",51,[15],[1897,1897],{"trials":1926,"activeCount":97},[1927,1935,1944,1952],{"nctId":1928,"briefTitle":1929,"status":119,"phases":1930,"primaryCompletion":1931,"completion":1931,"start":1932,"enrollment":1142,"conditions":1933,"interventions":1934},"NCT04235140","Long-term Safety of Lumacaftor\u002FIvacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to \u003C24 Months of Age at Treatment Initiation",[88],"2023-08-22","2020-02-24",[15],[1897],{"nctId":1936,"briefTitle":1937,"status":119,"phases":1938,"primaryCompletion":1939,"completion":1940,"start":499,"enrollment":1941,"conditions":1942,"interventions":1943},"NCT02544451","Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor",[88],"2018-08","2020-04",246,[15],[1897,1897],{"nctId":1945,"briefTitle":1946,"status":119,"phases":1947,"primaryCompletion":1948,"completion":1948,"start":1949,"enrollment":1832,"conditions":1950,"interventions":1951},"NCT02797132","Safety and Pharmacokinetic Study of Lumacaftor\u002FIvacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del",[88],"2017-09","2016-05",[15],[1897],{"nctId":1953,"briefTitle":1954,"status":119,"phases":1955,"primaryCompletion":1956,"completion":1956,"start":1957,"enrollment":657,"conditions":1958,"interventions":1959},"NCT03125395","A Rollover Safety Study of Lumacaftor\u002FIvacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation",[88],"2019-07-17","2017-05-12",[15],[1897],{"trials":1961,"activeCount":97},[1962,1970],{"nctId":1963,"briefTitle":1964,"status":119,"phases":1965,"primaryCompletion":1948,"completion":1966,"start":1967,"enrollment":597,"conditions":1968,"interventions":1969},"NCT02875366","A Study of the Effects of Lumacaftor\u002FIvacaftor (LUM\u002FIVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation",[89],"2017-10","2016-09",[15],[1897],{"nctId":1971,"briefTitle":1972,"status":403,"phases":1973,"primaryCompletion":334,"completion":334,"start":1974,"enrollment":1201,"conditions":1975,"interventions":1976},"NCT02823470","A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor\u002FIvacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation",[89],"2016-06",[15],[1897],{"trials":1978,"activeCount":97},[],{"intervention":1815,"totalTrials":304,"cells":1980},{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1985,"PHASE3":1991,"PHASE4":2001,"NA":2007},{"trials":1982,"activeCount":97},[],{"trials":1984,"activeCount":97},[],{"trials":1986,"activeCount":97},[1987],{"nctId":1809,"briefTitle":1810,"status":403,"phases":1988,"primaryCompletion":1812,"completion":1812,"start":1767,"enrollment":638,"conditions":1989,"interventions":1990},[87],[21],[1727,1696,1815,1816],{"trials":1992,"activeCount":97},[1993,1997],{"nctId":1857,"briefTitle":1858,"status":403,"phases":1994,"primaryCompletion":1775,"completion":1775,"start":1860,"enrollment":1861,"conditions":1995,"interventions":1996},[88],[21],[1727,1696,1815,1864],{"nctId":1866,"briefTitle":1867,"status":403,"phases":1998,"primaryCompletion":1869,"completion":1869,"start":1870,"enrollment":1871,"conditions":1999,"interventions":2000},[88],[1873],[1727,1815,1696],{"trials":2002,"activeCount":97},[2003],{"nctId":1887,"briefTitle":1888,"status":403,"phases":2004,"primaryCompletion":1890,"completion":1890,"start":1891,"enrollment":490,"conditions":2005,"interventions":2006},[89],[21],[1727,1696,1815],{"trials":2008,"activeCount":97},[],{"intervention":350,"totalTrials":93,"cells":2010},{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2037,"PHASE4":2071,"NA":2073},{"trials":2012,"activeCount":97},[],{"trials":2014,"activeCount":97},[],{"trials":2016,"activeCount":97},[2017,2021,2025,2029,2033],{"nctId":341,"briefTitle":342,"status":119,"phases":2018,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":2019,"interventions":2020},[87],[15],[349,350,310,326,351],{"nctId":353,"briefTitle":354,"status":119,"phases":2022,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":2023,"interventions":2024},[87],[15],[361,326,351,350,310],{"nctId":363,"briefTitle":364,"status":119,"phases":2026,"primaryCompletion":366,"completion":366,"start":367,"enrollment":368,"conditions":2027,"interventions":2028},[87],[15],[371,350,310],{"nctId":373,"briefTitle":374,"status":119,"phases":2030,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":2031,"interventions":2032},[86,87],[15],[361,350,310,361],{"nctId":382,"briefTitle":383,"status":119,"phases":2034,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":2035,"interventions":2036},[86,87],[15],[310,350,390,339,326,351,390],{"trials":2038,"activeCount":97},[2039,2043,2047,2051,2055,2059,2063,2067],{"nctId":476,"briefTitle":477,"status":119,"phases":2040,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":2041,"interventions":2042},[88],[15],[350,310],{"nctId":494,"briefTitle":495,"status":119,"phases":2044,"primaryCompletion":497,"completion":498,"start":499,"enrollment":500,"conditions":2045,"interventions":2046},[88],[15],[350,310],{"nctId":504,"briefTitle":505,"status":119,"phases":2048,"primaryCompletion":507,"completion":507,"start":508,"enrollment":16,"conditions":2049,"interventions":2050},[88],[15],[437,350,310],{"nctId":520,"briefTitle":521,"status":119,"phases":2052,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":2053,"interventions":2054},[88],[15],[350,310],{"nctId":555,"briefTitle":556,"status":119,"phases":2056,"primaryCompletion":558,"completion":559,"start":560,"enrollment":561,"conditions":2057,"interventions":2058},[88],[15],[465,350,310],{"nctId":601,"briefTitle":602,"status":119,"phases":2060,"primaryCompletion":604,"completion":604,"start":605,"enrollment":606,"conditions":2061,"interventions":2062},[88],[15],[427,310,350],{"nctId":617,"briefTitle":618,"status":119,"phases":2064,"primaryCompletion":620,"completion":620,"start":367,"enrollment":551,"conditions":2065,"interventions":2066},[88],[15],[326,350,310],{"nctId":697,"briefTitle":698,"status":119,"phases":2068,"primaryCompletion":700,"completion":700,"start":701,"enrollment":702,"conditions":2069,"interventions":2070},[88],[15],[427,350,310],{"trials":2072,"activeCount":97},[],{"trials":2074,"activeCount":97},[],{"intervention":1477,"totalTrials":28,"cells":2076},{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2107,"PHASE3":2117,"PHASE4":2134,"NA":2136},{"trials":2078,"activeCount":97},[],{"trials":2080,"activeCount":97},[2081,2092,2096],{"nctId":2082,"briefTitle":2083,"status":119,"phases":2084,"primaryCompletion":2085,"completion":2085,"start":1709,"enrollment":2086,"conditions":2087,"interventions":2088},"NCT01910415","Phase 1, QT\u002FQTC Interval Study in Healthy Subjects",[86],"2014-03",200,[15],[1477,2089,1478,2090,2091],"Lumacaftor Placebo","Ivacaftor Placebo","moxifloxacin hydrochloride",{"nctId":1470,"briefTitle":1471,"status":119,"phases":2093,"primaryCompletion":1473,"start":1474,"enrollment":368,"conditions":2094,"interventions":2095},[86],[15],[1477,1478,1479,1214,1480],{"nctId":2097,"briefTitle":2098,"status":119,"phases":2099,"primaryCompletion":2100,"completion":2100,"start":2101,"enrollment":2102,"conditions":2103,"interventions":2104},"NCT01899105","A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor",[86],"2013-08","2013-07",28,[15],[2105,2106],"lumacaftor","ivacaftor",{"trials":2108,"activeCount":97},[2109],{"nctId":2110,"briefTitle":2111,"status":119,"phases":2112,"primaryCompletion":1812,"completion":1812,"start":2113,"enrollment":2114,"conditions":2115,"interventions":2116},"NCT01225211","Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation",[87],"2010-10",312,[15],[1477,1478,2089,2090],{"trials":2118,"activeCount":97},[2119,2127],{"nctId":2120,"briefTitle":2121,"status":119,"phases":2122,"primaryCompletion":335,"completion":335,"start":2123,"enrollment":311,"conditions":2124,"interventions":2126},"NCT02390219","Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease",[88],"2015-03",[15,2125],"Advanced Lung Disease",[1477,1478],{"nctId":2128,"briefTitle":2129,"status":119,"phases":2130,"primaryCompletion":2131,"completion":2131,"start":2101,"enrollment":1832,"conditions":2132,"interventions":2133},"NCT01897233","Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation",[88],"2015-10",[15],[1477,1478],{"trials":2135,"activeCount":97},[],{"trials":2137,"activeCount":97},[],{"intervention":326,"totalTrials":28,"cells":2139},{"EARLY_PHASE1":2140,"PHASE1":2142,"PHASE2":2148,"PHASE3":2166,"PHASE4":2172,"NA":2174},{"trials":2141,"activeCount":97},[],{"trials":2143,"activeCount":97},[2144],{"nctId":318,"briefTitle":319,"status":119,"phases":2145,"primaryCompletion":321,"completion":321,"start":322,"enrollment":251,"conditions":2146,"interventions":2147},[86],[15],[325,326,310,327],{"trials":2149,"activeCount":97},[2150,2154,2158,2162],{"nctId":331,"briefTitle":332,"status":119,"phases":2151,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":2152,"interventions":2153},[87],[15],[326,310,325,339],{"nctId":341,"briefTitle":342,"status":119,"phases":2155,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":2156,"interventions":2157},[87],[15],[349,350,310,326,351],{"nctId":353,"briefTitle":354,"status":119,"phases":2159,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":2160,"interventions":2161},[87],[15],[361,326,351,350,310],{"nctId":382,"briefTitle":383,"status":119,"phases":2163,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":2164,"interventions":2165},[86,87],[15],[310,350,390,339,326,351,390],{"trials":2167,"activeCount":97},[2168],{"nctId":617,"briefTitle":618,"status":119,"phases":2169,"primaryCompletion":620,"completion":620,"start":367,"enrollment":551,"conditions":2170,"interventions":2171},[88],[15],[326,350,310],{"trials":2173,"activeCount":97},[],{"trials":2175,"activeCount":97},[],{"intervention":2177,"totalTrials":28,"cells":2178},"VX-509",{"EARLY_PHASE1":2179,"PHASE1":2181,"PHASE2":2200,"PHASE3":2226,"PHASE4":2235,"NA":2237},{"trials":2180,"activeCount":97},[],{"trials":2182,"activeCount":97},[2183,2191],{"nctId":2184,"briefTitle":2185,"status":119,"phases":2186,"start":1852,"enrollment":2187,"conditions":2188,"interventions":2190},"NCT00789126","Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects",[86],72,[2189],"Healthy",[2177],{"nctId":2192,"briefTitle":2193,"status":119,"phases":2194,"primaryCompletion":2100,"completion":2100,"start":1709,"enrollment":2102,"conditions":2195,"interventions":2197},"NCT01886209","Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects",[86],[2196],"Drug Interactions",[2198,2177,2199],"Prednisone","Methylprednisolone",{"trials":2201,"activeCount":97},[2202,2209,2217],{"nctId":2203,"briefTitle":2204,"status":119,"phases":2205,"primaryCompletion":1869,"completion":1775,"start":1474,"enrollment":2206,"conditions":2207,"interventions":2208},"NCT01754935","A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor",[87],43,[30],[2177],{"nctId":2210,"briefTitle":2211,"status":119,"phases":2212,"primaryCompletion":2213,"completion":2213,"start":1784,"enrollment":2214,"conditions":2215,"interventions":2216},"NCT01052194","A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis",[87],"2011-07",206,[30],[2177,2177,2177,2177],{"nctId":2218,"briefTitle":2219,"status":119,"phases":2220,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":2223,"conditions":2224,"interventions":2225},"NCT01590459","24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate",[87],"2014-07","2012-04",359,[30],[2177],{"trials":2227,"activeCount":97},[2228],{"nctId":2229,"briefTitle":2230,"status":119,"phases":2231,"primaryCompletion":2221,"completion":2221,"start":2232,"enrollment":1241,"conditions":2233,"interventions":2234},"NCT01830985","A Phase 2\u002F3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis",[87,88],"2013-04",[30],[2177],{"trials":2236,"activeCount":97},[],{"trials":2238,"activeCount":97},[],{"intervention":183,"totalTrials":28,"cells":2240},{"EARLY_PHASE1":2241,"PHASE1":2243,"PHASE2":2245,"PHASE3":2281,"PHASE4":2297,"NA":2299},{"trials":2242,"activeCount":97},[],{"trials":2244,"activeCount":97},[],{"trials":2246,"activeCount":97},[2247,2257,2261,2271],{"nctId":2248,"briefTitle":2249,"status":119,"phases":2250,"primaryCompletion":2251,"completion":2252,"start":2253,"enrollment":2254,"conditions":2255,"interventions":2256},"NCT05034952","A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty",[87],"2021-12-05","2021-12-21","2021-08-30",303,[24],[1255,183],{"nctId":1259,"briefTitle":1260,"status":119,"phases":2258,"primaryCompletion":1262,"completion":1262,"start":1263,"enrollment":1264,"conditions":2259,"interventions":2260},[87],[24],[813,183],{"nctId":2262,"briefTitle":2263,"status":119,"phases":2264,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":2268,"conditions":2269,"interventions":2270},"NCT03206749","A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy",[87],"2017-12-01","2017-12-08","2017-06-29",243,[24],[1254,183],{"nctId":2272,"briefTitle":2273,"status":119,"phases":2274,"primaryCompletion":2275,"completion":2276,"start":2277,"enrollment":2278,"conditions":2279,"interventions":2280},"NCT04977336","A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy",[87],"2022-02-17","2022-03-04","2021-07-19",274,[24],[1255,183],{"trials":2282,"activeCount":97},[2283,2287],{"nctId":174,"briefTitle":175,"status":119,"phases":2284,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":2285,"interventions":2286},[88],[24],[58,183],{"nctId":2288,"briefTitle":2289,"status":119,"phases":2290,"primaryCompletion":2291,"completion":2291,"start":2292,"enrollment":2293,"conditions":2294,"interventions":2295},"NCT05553366","Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy",[88],"2023-12-15","2022-10-03",1075,[24],[2296,183],"SUZ",{"trials":2298,"activeCount":97},[],{"trials":2300,"activeCount":97},[],{"intervention":1728,"totalTrials":12,"cells":2302},{"EARLY_PHASE1":2303,"PHASE1":2305,"PHASE2":2307,"PHASE3":2325,"PHASE4":2331,"NA":2333},{"trials":2304,"activeCount":97},[],{"trials":2306,"activeCount":97},[],{"trials":2308,"activeCount":97},[2309,2313,2317,2321],{"nctId":1718,"briefTitle":1719,"status":119,"phases":2310,"primaryCompletion":1721,"completion":1722,"start":1723,"enrollment":1724,"conditions":2311,"interventions":2312},[87],[21],[1727,1696,1728],{"nctId":1781,"briefTitle":1782,"status":119,"phases":2314,"primaryCompletion":1784,"completion":1784,"start":1785,"enrollment":1786,"conditions":2315,"interventions":2316},[87],[21],[1727,1696,1789],{"nctId":1791,"briefTitle":1792,"status":119,"phases":2318,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1797,"conditions":2319,"interventions":2320},[87],[32],[1696,1728,1727],{"nctId":1818,"briefTitle":1819,"status":119,"phases":2322,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":1823,"conditions":2323,"interventions":2324},[87],[32],[1727,1696,1728],{"trials":2326,"activeCount":97},[2327],{"nctId":1876,"briefTitle":1877,"status":119,"phases":2328,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":2329,"interventions":2330},[88],[21],[1728,1727,1696],{"trials":2332,"activeCount":97},[],{"trials":2334,"activeCount":97},[],{"intervention":465,"totalTrials":304,"cells":2336},{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2341,"PHASE3":2343,"PHASE4":2361,"NA":2363},{"trials":2338,"activeCount":97},[],{"trials":2340,"activeCount":97},[],{"trials":2342,"activeCount":97},[],{"trials":2344,"activeCount":97},[2345,2349,2353,2357],{"nctId":457,"briefTitle":458,"status":119,"phases":2346,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":2347,"interventions":2348},[88],[15],[465,310],{"nctId":555,"briefTitle":556,"status":119,"phases":2350,"primaryCompletion":558,"completion":559,"start":560,"enrollment":561,"conditions":2351,"interventions":2352},[88],[15],[465,350,310],{"nctId":583,"briefTitle":584,"status":403,"phases":2354,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":2355,"interventions":2356},[88],[15],[465,310],{"nctId":610,"briefTitle":611,"status":403,"phases":2358,"primaryCompletion":613,"completion":613,"start":508,"enrollment":22,"conditions":2359,"interventions":2360},[88],[15],[465,310],{"trials":2362,"activeCount":97},[],{"trials":2364,"activeCount":97},[],{"intervention":2366,"totalTrials":304,"cells":2367},"VX-809",{"EARLY_PHASE1":2368,"PHASE1":2370,"PHASE2":2391,"PHASE3":2401,"PHASE4":2410,"NA":2412},{"trials":2369,"activeCount":97},[],{"trials":2371,"activeCount":97},[2372,2382],{"nctId":2373,"briefTitle":2374,"status":119,"phases":2375,"primaryCompletion":2376,"completion":2376,"start":2377,"enrollment":1201,"conditions":2378,"interventions":2379},"NCT00966602","Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects",[86],"2009-12","2009-09",[15],[2366,2380,2381],"VX-770","VX-809 & VX-770",{"nctId":2383,"briefTitle":2384,"status":119,"phases":2385,"primaryCompletion":2386,"completion":2386,"start":2113,"enrollment":123,"conditions":2387,"interventions":2388},"NCT01216046","Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects",[86],"2011-05",[15],[2366,2380,2389,2390],"VX-809 placebo","VX-770 placebo",{"trials":2392,"activeCount":97},[2393],{"nctId":2394,"briefTitle":2395,"status":119,"phases":2396,"primaryCompletion":2376,"completion":2376,"start":2397,"enrollment":2398,"conditions":2399,"interventions":2400},"NCT00865904","Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation",[87],"2009-03",93,[15],[2366],{"trials":2402,"activeCount":97},[2403],{"nctId":2404,"briefTitle":2405,"status":119,"phases":2406,"primaryCompletion":1967,"completion":1967,"start":2407,"enrollment":2214,"conditions":2408,"interventions":2409},"NCT02514473","A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation",[88],"2015-07",[15],[2366,2380],{"trials":2411,"activeCount":97},[],{"trials":2413,"activeCount":97},[],{"intervention":1762,"totalTrials":304,"cells":2415},{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2420,"PHASE3":2434,"PHASE4":2440,"NA":2442},{"trials":2417,"activeCount":97},[],{"trials":2419,"activeCount":97},[],{"trials":2421,"activeCount":97},[2422,2426,2430],{"nctId":1754,"briefTitle":1755,"status":119,"phases":2423,"completion":1757,"start":1758,"enrollment":113,"conditions":2424,"interventions":2425},[87],[21],[1761,1716,1762],{"nctId":1827,"briefTitle":1828,"status":119,"phases":2427,"primaryCompletion":1830,"start":1831,"enrollment":1832,"conditions":2428,"interventions":2429},[87],[21,1834],[1762,1716,1716],{"nctId":1837,"briefTitle":1838,"status":119,"phases":2431,"primaryCompletion":1840,"completion":1840,"start":1722,"enrollment":1841,"conditions":2432,"interventions":2433},[86,87],[21],[1762,1716],{"trials":2435,"activeCount":97},[2436],{"nctId":1847,"briefTitle":1848,"status":119,"phases":2437,"primaryCompletion":1850,"completion":1851,"start":1852,"enrollment":1853,"conditions":2438,"interventions":2439},[88],[21],[1089,1716,1762],{"trials":2441,"activeCount":97},[],{"trials":2443,"activeCount":97},[],{"intervention":2090,"totalTrials":203,"cells":2445},{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2454,"PHASE3":2460,"PHASE4":2474,"NA":2476},{"trials":2447,"activeCount":97},[],{"trials":2449,"activeCount":97},[2450],{"nctId":2082,"briefTitle":2083,"status":119,"phases":2451,"primaryCompletion":2085,"completion":2085,"start":1709,"enrollment":2086,"conditions":2452,"interventions":2453},[86],[15],[1477,2089,1478,2090,2091],{"trials":2455,"activeCount":97},[2456],{"nctId":2110,"briefTitle":2111,"status":119,"phases":2457,"primaryCompletion":1812,"completion":1812,"start":2113,"enrollment":2114,"conditions":2458,"interventions":2459},[87],[15],[1477,1478,2089,2090],{"trials":2461,"activeCount":97},[2462],{"nctId":2463,"briefTitle":2464,"status":119,"phases":2465,"primaryCompletion":2466,"completion":2466,"start":2467,"enrollment":2468,"conditions":2469,"interventions":2470},"NCT02347657","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor",[88],"2017-01-20","2015-01",510,[15],[2471,1478,2472,2473],"VX-661 Plus Ivacaftor Combination","VX-661 Plus Ivacaftor Combination Placebo","Ivacaftor placebo",{"trials":2475,"activeCount":97},[],{"trials":2477,"activeCount":97},[],{"intervention":2479,"totalTrials":203,"cells":2480},"Lumacaftor Plus Ivacaftor Combination",{"EARLY_PHASE1":2481,"PHASE1":2483,"PHASE2":2485,"PHASE3":2487,"PHASE4":2513,"NA":2515},{"trials":2482,"activeCount":97},[],{"trials":2484,"activeCount":97},[],{"trials":2486,"activeCount":97},[],{"trials":2488,"activeCount":97},[2489,2498,2507],{"nctId":2490,"briefTitle":2491,"status":119,"phases":2492,"primaryCompletion":1812,"completion":1812,"start":2493,"enrollment":2494,"conditions":2495,"interventions":2497},"NCT01807923","A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation",[88],"2013-05",559,[2496],"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",[2479,1478],{"nctId":2499,"briefTitle":2500,"status":119,"phases":2501,"primaryCompletion":2502,"completion":2502,"start":1733,"enrollment":2503,"conditions":2504,"interventions":2506},"NCT01931839","A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis",[88],"2016-04",1164,[2505],"Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation",[2479,1478],{"nctId":2508,"briefTitle":2491,"status":119,"phases":2509,"primaryCompletion":1812,"completion":1812,"start":2232,"enrollment":2510,"conditions":2511,"interventions":2512},"NCT01807949",[88],563,[2496],[2479,1478],{"trials":2514,"activeCount":97},[],{"trials":2516,"activeCount":97},[],{"intervention":437,"totalTrials":137,"cells":2518},{"EARLY_PHASE1":2519,"PHASE1":2521,"PHASE2":2523,"PHASE3":2525,"PHASE4":2535,"NA":2537},{"trials":2520,"activeCount":97},[],{"trials":2522,"activeCount":97},[],{"trials":2524,"activeCount":97},[],{"trials":2526,"activeCount":97},[2527,2531],{"nctId":429,"briefTitle":430,"status":119,"phases":2528,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":2529,"interventions":2530},[88],[15],[437,310],{"nctId":504,"briefTitle":505,"status":119,"phases":2532,"primaryCompletion":507,"completion":507,"start":508,"enrollment":16,"conditions":2533,"interventions":2534},[88],[15],[437,350,310],{"trials":2536,"activeCount":97},[],{"trials":2538,"activeCount":97},[],{"intervention":2471,"totalTrials":137,"cells":2540},{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2545,"PHASE3":2547,"PHASE4":2562,"NA":2564},{"trials":2542,"activeCount":97},[],{"trials":2544,"activeCount":97},[],{"trials":2546,"activeCount":97},[],{"trials":2548,"activeCount":97},[2549,2553],{"nctId":2463,"briefTitle":2464,"status":119,"phases":2550,"primaryCompletion":2466,"completion":2466,"start":2467,"enrollment":2468,"conditions":2551,"interventions":2552},[88],[15],[2471,1478,2472,2473],{"nctId":2554,"briefTitle":2555,"status":119,"phases":2556,"primaryCompletion":2557,"completion":2557,"start":499,"enrollment":2558,"conditions":2559,"interventions":2560},"NCT02516410","A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation",[88],"2016-06-07",168,[15],[2561,1478],"VX-661 plus ivacaftor combination",{"trials":2563,"activeCount":97},[],{"trials":2565,"activeCount":97},[],{"intervention":2296,"totalTrials":137,"cells":2567},{"EARLY_PHASE1":2568,"PHASE1":2570,"PHASE2":2580,"PHASE3":2582,"PHASE4":2588,"NA":2590},{"trials":2569,"activeCount":97},[],{"trials":2571,"activeCount":97},[2572],{"nctId":2573,"briefTitle":2574,"status":119,"phases":2575,"primaryCompletion":2576,"completion":2576,"start":2577,"enrollment":25,"conditions":2578,"interventions":2579},"NCT06834009","A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists",[86],"2025-04-24","2025-03-10",[18],[2296],{"trials":2581,"activeCount":97},[],{"trials":2583,"activeCount":97},[2584],{"nctId":2288,"briefTitle":2289,"status":119,"phases":2585,"primaryCompletion":2291,"completion":2291,"start":2292,"enrollment":2293,"conditions":2586,"interventions":2587},[88],[24],[2296,183],{"trials":2589,"activeCount":97},[],{"trials":2591,"activeCount":97},[],{"intervention":2472,"totalTrials":235,"cells":2593},{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2606,"NA":2608},{"trials":2595,"activeCount":97},[],{"trials":2597,"activeCount":97},[],{"trials":2599,"activeCount":97},[],{"trials":2601,"activeCount":97},[2602],{"nctId":2463,"briefTitle":2464,"status":119,"phases":2603,"primaryCompletion":2466,"completion":2466,"start":2467,"enrollment":2468,"conditions":2604,"interventions":2605},[88],[15],[2471,1478,2472,2473],{"trials":2607,"activeCount":97},[],{"trials":2609,"activeCount":97},[],{"intervention":2611,"totalTrials":235,"cells":2612},"Exa-cel",{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2617,"PHASE3":2619,"PHASE4":2630,"NA":2632},{"trials":2614,"activeCount":97},[],{"trials":2616,"activeCount":97},[],{"trials":2618,"activeCount":97},[],{"trials":2620,"activeCount":97},[2621],{"nctId":2622,"briefTitle":2623,"status":2624,"phases":2625,"primaryCompletion":2626,"completion":2626,"start":2627,"enrollment":97,"conditions":2628,"interventions":2629},"NCT05951205","Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS\u002F βC Genotype","WITHDRAWN",[88],"2033-12-31","2027-07-31",[275],[2611],{"trials":2631,"activeCount":97},[],{"trials":2633,"activeCount":97},[],{"intervention":1864,"totalTrials":235,"cells":2635},{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2640,"PHASE3":2642,"PHASE4":2648,"NA":2650},{"trials":2637,"activeCount":97},[],{"trials":2639,"activeCount":97},[],{"trials":2641,"activeCount":97},[],{"trials":2643,"activeCount":97},[2644],{"nctId":1857,"briefTitle":1858,"status":403,"phases":2645,"primaryCompletion":1775,"completion":1775,"start":1860,"enrollment":1861,"conditions":2646,"interventions":2647},[88],[21],[1727,1696,1815,1864],{"trials":2649,"activeCount":97},[],{"trials":2651,"activeCount":97},[],{"intervention":641,"totalTrials":235,"cells":2653},{"EARLY_PHASE1":2654,"PHASE1":2656,"PHASE2":2658,"PHASE3":2660,"PHASE4":2666,"NA":2668},{"trials":2655,"activeCount":97},[],{"trials":2657,"activeCount":97},[],{"trials":2659,"activeCount":97},[],{"trials":2661,"activeCount":97},[2662],{"nctId":633,"briefTitle":634,"status":119,"phases":2663,"primaryCompletion":636,"completion":636,"start":637,"enrollment":638,"conditions":2664,"interventions":2665},[88],[15],[641,310],{"trials":2667,"activeCount":97},[],{"trials":2669,"activeCount":97},[],{"intervention":2671,"totalTrials":235,"cells":2672},"VX-210",{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2679,"PHASE4":2690,"NA":2692},{"trials":2674,"activeCount":97},[],{"trials":2676,"activeCount":97},[],{"trials":2678,"activeCount":97},[],{"trials":2680,"activeCount":97},[2681],{"nctId":2682,"briefTitle":2683,"status":403,"phases":2684,"primaryCompletion":2685,"completion":2685,"start":2686,"enrollment":597,"conditions":2687,"interventions":2689},"NCT02669849","Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury",[87,88],"2018-11","2016-07",[2688],"Cervical Spinal Cord Injury",[2671],{"trials":2691,"activeCount":97},[],{"trials":2693,"activeCount":97},[],{"intervention":2695,"totalTrials":235,"cells":2696},"VX-661\u002FIvacaftor",{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2703,"PHASE4":2713,"NA":2715},{"trials":2698,"activeCount":97},[],{"trials":2700,"activeCount":97},[],{"trials":2702,"activeCount":97},[],{"trials":2704,"activeCount":97},[2705],{"nctId":2706,"briefTitle":2707,"status":119,"phases":2708,"primaryCompletion":2709,"completion":2709,"start":2123,"enrollment":2710,"conditions":2711,"interventions":2712},"NCT02392234","A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation",[88],"2017-02",248,[15],[2695,1478],{"trials":2714,"activeCount":97},[],{"trials":2716,"activeCount":97},[],{"intervention":1255,"totalTrials":406,"cells":2718},{"EARLY_PHASE1":2719,"PHASE1":2721,"PHASE2":2786,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2720,"activeCount":97},[],{"trials":2722,"activeCount":97},[2723,2731,2738,2748,2760,2764,2773,2782],{"nctId":2724,"briefTitle":2725,"status":119,"phases":2726,"primaryCompletion":2727,"completion":2727,"start":412,"enrollment":2728,"conditions":2729,"interventions":2730},"NCT05704556","Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment",[86],"2024-03-30",38,[18],[1255],{"nctId":2732,"briefTitle":2733,"status":119,"phases":2734,"primaryCompletion":1402,"completion":1402,"start":2735,"enrollment":1201,"conditions":2736,"interventions":2737},"NCT05455502","A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548",[86],"2022-07-13",[18],[1255],{"nctId":2739,"briefTitle":2740,"status":119,"phases":2741,"primaryCompletion":2742,"completion":2743,"start":2744,"enrollment":2745,"conditions":2746,"interventions":2747},"NCT05851157","A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548",[86],"2023-10-30","2023-11-08","2023-05-03",73,[18],[1255],{"nctId":2749,"briefTitle":2750,"status":119,"phases":2751,"primaryCompletion":2752,"completion":2753,"start":2754,"enrollment":2187,"conditions":2755,"interventions":2756},"NCT05818852","A Study to Evaluate the Effect of VX-548 on the QT\u002FQTc Interval in Healthy Participants",[86],"2023-06-12","2023-06-28","2023-04-12",[18],[1255,2757,2758,2759],"Moxifloxacin","Moxifloxacin Placebo","VX-548 Placebo",{"nctId":1420,"briefTitle":1421,"status":119,"phases":2761,"primaryCompletion":1423,"completion":1424,"start":1425,"enrollment":1426,"conditions":2762,"interventions":2763},[86],[18],[1255,1215,1429],{"nctId":2765,"briefTitle":2766,"status":119,"phases":2767,"primaryCompletion":2768,"completion":2768,"start":2769,"enrollment":2770,"conditions":2771,"interventions":2772},"NCT05560464","Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment",[86],"2023-07-24","2022-10-14",36,[18],[1255],{"nctId":2774,"briefTitle":2775,"status":119,"phases":2776,"primaryCompletion":2777,"completion":2777,"start":2778,"enrollment":1231,"conditions":2779,"interventions":2780},"NCT05635110","Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants",[86],"2023-06-08","2022-12-15",[18],[1255,2781,1480],"Omeprazole",{"nctId":1245,"briefTitle":1246,"status":119,"phases":2783,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":1251,"conditions":2784,"interventions":2785},[86],[18],[1254,1255,813],{"trials":2787,"activeCount":97},[2788,2799,2803],{"nctId":2789,"briefTitle":2790,"status":119,"phases":2791,"primaryCompletion":2792,"completion":2793,"start":2794,"enrollment":2795,"conditions":2796,"interventions":2798},"NCT06176196","Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)",[87],"2024-10-02","2024-10-16","2023-12-13",218,[2797],"Painful Lumbosacral Radiculopathy",[1255],{"nctId":2248,"briefTitle":2249,"status":119,"phases":2800,"primaryCompletion":2251,"completion":2252,"start":2253,"enrollment":2254,"conditions":2801,"interventions":2802},[87],[24],[1255,183],{"nctId":2272,"briefTitle":2273,"status":119,"phases":2804,"primaryCompletion":2275,"completion":2276,"start":2277,"enrollment":2278,"conditions":2805,"interventions":2806},[87],[24],[1255,183],{"trials":2808,"activeCount":97},[],{"trials":2810,"activeCount":97},[],{"trials":2812,"activeCount":97},[],{"intervention":1254,"totalTrials":28,"cells":2814},{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2833,"PHASE3":2869,"PHASE4":2871,"NA":2873},{"trials":2816,"activeCount":97},[],{"trials":2818,"activeCount":97},[2819,2829],{"nctId":2820,"briefTitle":2821,"status":119,"phases":2822,"primaryCompletion":2823,"completion":2824,"start":2825,"enrollment":2826,"conditions":2827,"interventions":2828},"NCT05418712","A Microneurography (MNG) Study of VX-150 in Healthy Participants",[86],"2022-09-14","2022-09-23","2022-06-16",45,[18],[1254],{"nctId":1245,"briefTitle":1246,"status":119,"phases":2830,"primaryCompletion":1248,"completion":1249,"start":1250,"enrollment":1251,"conditions":2831,"interventions":2832},[86],[18],[1254,1255,813],{"trials":2834,"activeCount":97},[2835,2844,2848,2859],{"nctId":2836,"briefTitle":2837,"status":119,"phases":2838,"primaryCompletion":2839,"completion":1967,"start":2840,"enrollment":346,"conditions":2841,"interventions":2843},"NCT02660424","A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee",[87],"2016-08","2015-12",[2842],"Osteoarthritis",[1254],{"nctId":2262,"briefTitle":2263,"status":119,"phases":2845,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":2268,"conditions":2846,"interventions":2847},[87],[24],[1254,183],{"nctId":2849,"briefTitle":2850,"status":119,"phases":2851,"primaryCompletion":2852,"completion":2853,"start":2854,"enrollment":2855,"conditions":2856,"interventions":2858},"NCT03304522","A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy",[87],"2018-10-12","2018-11-08","2017-09-20",89,[2857],"Small Fiber Neuropathy",[1254],{"nctId":2860,"briefTitle":2861,"status":119,"phases":2862,"primaryCompletion":2863,"completion":2864,"start":2865,"enrollment":2866,"conditions":2867,"interventions":2868},"NCT03764072","A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy",[87],"2019-01-17","2019-01-25","2018-12-12",250,[24],[1254],{"trials":2870,"activeCount":97},[],{"trials":2872,"activeCount":97},[],{"trials":2874,"activeCount":97},[],{"intervention":351,"totalTrials":12,"cells":2876},{"EARLY_PHASE1":2877,"PHASE1":2879,"PHASE2":2881,"PHASE3":2903,"PHASE4":2905,"NA":2907},{"trials":2878,"activeCount":97},[],{"trials":2880,"activeCount":97},[],{"trials":2882,"activeCount":97},[2883,2887,2891,2895,2899],{"nctId":341,"briefTitle":342,"status":119,"phases":2884,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":2885,"interventions":2886},[87],[15],[349,350,310,326,351],{"nctId":353,"briefTitle":354,"status":119,"phases":2888,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":2889,"interventions":2890},[87],[15],[361,326,351,350,310],{"nctId":382,"briefTitle":383,"status":119,"phases":2892,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":2893,"interventions":2894},[86,87],[15],[310,350,390,339,326,351,390],{"nctId":392,"briefTitle":393,"status":119,"phases":2896,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":2897,"interventions":2898},[87],[15],[351,310],{"nctId":401,"briefTitle":402,"status":403,"phases":2900,"primaryCompletion":334,"completion":334,"start":405,"enrollment":406,"conditions":2901,"interventions":2902},[87],[15],[351,310],{"trials":2904,"activeCount":97},[],{"trials":2906,"activeCount":97},[],{"trials":2908,"activeCount":97},[],{"intervention":1715,"totalTrials":203,"cells":2910},{"EARLY_PHASE1":2911,"PHASE1":2913,"PHASE2":2915,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2912,"activeCount":97},[],{"trials":2914,"activeCount":97},[],{"trials":2916,"activeCount":97},[2917,2921,2925],{"nctId":1706,"briefTitle":1707,"status":119,"phases":2918,"primaryCompletion":1709,"completion":1710,"start":1711,"enrollment":648,"conditions":2919,"interventions":2920},[87],[1713],[1715,1089,1716],{"nctId":1730,"briefTitle":1731,"status":403,"phases":2922,"primaryCompletion":1733,"completion":1734,"start":1735,"enrollment":1736,"conditions":2923,"interventions":2924},[87],[1738],[1089,1715,1716,1740,1715],{"nctId":1764,"briefTitle":1765,"status":119,"phases":2926,"primaryCompletion":1473,"completion":1710,"start":1767,"enrollment":1768,"conditions":2927,"interventions":2928},[87],[1713],[1715,1089,1716,1740],{"trials":2930,"activeCount":97},[],{"trials":2932,"activeCount":97},[],{"trials":2934,"activeCount":97},[],{"intervention":2936,"totalTrials":203,"cells":2937},"VX-661",{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2949,"PHASE3":2965,"PHASE4":2967,"NA":2969},{"trials":2939,"activeCount":97},[],{"trials":2941,"activeCount":97},[2942],{"nctId":2943,"briefTitle":2944,"status":119,"phases":2945,"primaryCompletion":1775,"completion":1775,"start":1869,"enrollment":989,"conditions":2946,"interventions":2947},"NCT02015507","An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor",[86],[15],[2106,2936,2948],"ciprofloxacin",{"trials":2950,"activeCount":97},[2951,2957],{"nctId":2952,"briefTitle":2953,"status":119,"phases":2954,"primaryCompletion":2085,"completion":2085,"start":1767,"enrollment":147,"conditions":2955,"interventions":2956},"NCT01531673","Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation",[87],[15],[2936,1478],{"nctId":2958,"briefTitle":2959,"status":119,"phases":2960,"primaryCompletion":2961,"completion":2961,"start":2085,"enrollment":2962,"conditions":2963,"interventions":2964},"NCT02070744","Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion",[87],"2016-05-27",40,[15],[2936,1478],{"trials":2966,"activeCount":97},[],{"trials":2968,"activeCount":97},[],{"trials":2970,"activeCount":97},[],{"intervention":2089,"totalTrials":137,"cells":2972},{"EARLY_PHASE1":2973,"PHASE1":2975,"PHASE2":2981,"PHASE3":2987,"PHASE4":2989,"NA":2991},{"trials":2974,"activeCount":97},[],{"trials":2976,"activeCount":97},[2977],{"nctId":2082,"briefTitle":2083,"status":119,"phases":2978,"primaryCompletion":2085,"completion":2085,"start":1709,"enrollment":2086,"conditions":2979,"interventions":2980},[86],[15],[1477,2089,1478,2090,2091],{"trials":2982,"activeCount":97},[2983],{"nctId":2110,"briefTitle":2111,"status":119,"phases":2984,"primaryCompletion":1812,"completion":1812,"start":2113,"enrollment":2114,"conditions":2985,"interventions":2986},[87],[15],[1477,1478,2089,2090],{"trials":2988,"activeCount":97},[],{"trials":2990,"activeCount":97},[],{"trials":2992,"activeCount":97},[],{"intervention":325,"totalTrials":137,"cells":2994},{"EARLY_PHASE1":2995,"PHASE1":2997,"PHASE2":3003,"PHASE3":3009,"PHASE4":3011,"NA":3013},{"trials":2996,"activeCount":97},[],{"trials":2998,"activeCount":97},[2999],{"nctId":318,"briefTitle":319,"status":119,"phases":3000,"primaryCompletion":321,"completion":321,"start":322,"enrollment":251,"conditions":3001,"interventions":3002},[86],[15],[325,326,310,327],{"trials":3004,"activeCount":97},[3005],{"nctId":331,"briefTitle":332,"status":119,"phases":3006,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":3007,"interventions":3008},[87],[15],[326,310,325,339],{"trials":3010,"activeCount":97},[],{"trials":3012,"activeCount":97},[],{"trials":3014,"activeCount":97},[],{"intervention":1740,"totalTrials":137,"cells":3016},{"EARLY_PHASE1":3017,"PHASE1":3019,"PHASE2":3021,"PHASE3":3031,"PHASE4":3033,"NA":3035},{"trials":3018,"activeCount":97},[],{"trials":3020,"activeCount":97},[],{"trials":3022,"activeCount":97},[3023,3027],{"nctId":1730,"briefTitle":1731,"status":403,"phases":3024,"primaryCompletion":1733,"completion":1734,"start":1735,"enrollment":1736,"conditions":3025,"interventions":3026},[87],[1738],[1089,1715,1716,1740,1715],{"nctId":1764,"briefTitle":1765,"status":119,"phases":3028,"primaryCompletion":1473,"completion":1710,"start":1767,"enrollment":1768,"conditions":3029,"interventions":3030},[87],[1713],[1715,1089,1716,1740],{"trials":3032,"activeCount":97},[],{"trials":3034,"activeCount":97},[],{"trials":3036,"activeCount":97},[],{"intervention":339,"totalTrials":137,"cells":3038},{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3043,"PHASE3":3053,"PHASE4":3055,"NA":3057},{"trials":3040,"activeCount":97},[],{"trials":3042,"activeCount":97},[],{"trials":3044,"activeCount":97},[3045,3049],{"nctId":331,"briefTitle":332,"status":119,"phases":3046,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":3047,"interventions":3048},[87],[15],[326,310,325,339],{"nctId":382,"briefTitle":383,"status":119,"phases":3050,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":3051,"interventions":3052},[86,87],[15],[310,350,390,339,326,351,390],{"trials":3054,"activeCount":97},[],{"trials":3056,"activeCount":97},[],{"trials":3058,"activeCount":97},[],{"intervention":349,"totalTrials":137,"cells":3060},{"EARLY_PHASE1":3061,"PHASE1":3063,"PHASE2":3069,"PHASE3":3075,"PHASE4":3077,"NA":3079},{"trials":3062,"activeCount":97},[],{"trials":3064,"activeCount":97},[3065],{"nctId":1508,"briefTitle":1509,"status":119,"phases":3066,"primaryCompletion":334,"completion":334,"start":367,"enrollment":1511,"conditions":3067,"interventions":3068},[86],[15],[349,1448,1478],{"trials":3070,"activeCount":97},[3071],{"nctId":341,"briefTitle":342,"status":119,"phases":3072,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":3073,"interventions":3074},[87],[15],[349,350,310,326,351],{"trials":3076,"activeCount":97},[],{"trials":3078,"activeCount":97},[],{"trials":3080,"activeCount":97},[],{"intervention":361,"totalTrials":137,"cells":3082},{"EARLY_PHASE1":3083,"PHASE1":3085,"PHASE2":3087,"PHASE3":3097,"PHASE4":3099,"NA":3101},{"trials":3084,"activeCount":97},[],{"trials":3086,"activeCount":97},[],{"trials":3088,"activeCount":97},[3089,3093],{"nctId":353,"briefTitle":354,"status":119,"phases":3090,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":3091,"interventions":3092},[87],[15],[361,326,351,350,310],{"nctId":373,"briefTitle":374,"status":119,"phases":3094,"primaryCompletion":376,"completion":376,"start":377,"enrollment":378,"conditions":3095,"interventions":3096},[86,87],[15],[361,350,310,361],{"trials":3098,"activeCount":97},[],{"trials":3100,"activeCount":97},[],{"trials":3102,"activeCount":97},[],{"intervention":1779,"totalTrials":137,"cells":3104},{"EARLY_PHASE1":3105,"PHASE1":3107,"PHASE2":3109,"PHASE3":3124,"PHASE4":3126,"NA":3128},{"trials":3106,"activeCount":97},[],{"trials":3108,"activeCount":97},[],{"trials":3110,"activeCount":97},[3111,3120],{"nctId":3112,"briefTitle":3113,"status":119,"phases":3114,"primaryCompletion":1890,"completion":1890,"start":1709,"enrollment":870,"conditions":3115,"interventions":3118},"NCT01842451","A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C",[87],[32,3116,3117,21],"CHC","HCV",[1779,3119],"Daclatasvir",{"nctId":1772,"briefTitle":1773,"status":119,"phases":3121,"primaryCompletion":1775,"completion":1775,"start":1776,"enrollment":25,"conditions":3122,"interventions":3123},[87],[32],[1779,1716],{"trials":3125,"activeCount":97},[],{"trials":3127,"activeCount":97},[],{"trials":3129,"activeCount":97},[],{"intervention":3131,"totalTrials":137,"cells":3132},"VX-864",{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3157,"PHASE4":3159,"NA":3161},{"trials":3134,"activeCount":97},[],{"trials":3136,"activeCount":97},[],{"trials":3138,"activeCount":97},[3139,3149],{"nctId":3140,"briefTitle":3141,"status":403,"phases":3142,"primaryCompletion":3143,"completion":3143,"start":3144,"enrollment":3145,"conditions":3146,"interventions":3148},"NCT05643495","A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype",[87],"2024-08-19","2023-02-23",14,[3147],"Alpha-1 Antitrypsin Deficiency",[3131],{"nctId":3150,"briefTitle":3151,"status":119,"phases":3152,"primaryCompletion":3153,"completion":3153,"start":700,"enrollment":1163,"conditions":3154,"interventions":3156},"NCT04474197","Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype",[87],"2021-05-04",[3155],"Alpha1-Antitrypsin Deficiency",[3131],{"trials":3158,"activeCount":97},[],{"trials":3160,"activeCount":97},[],{"trials":3162,"activeCount":97},[],{"intervention":1761,"totalTrials":137,"cells":3164},{"EARLY_PHASE1":3165,"PHASE1":3167,"PHASE2":3178,"PHASE3":3184,"PHASE4":3186,"NA":3188},{"trials":3166,"activeCount":97},[],{"trials":3168,"activeCount":97},[3169],{"nctId":3170,"briefTitle":3171,"status":119,"phases":3172,"completion":3173,"start":3174,"enrollment":1086,"conditions":3175,"interventions":3176},"NCT00251199","VX-950 and Peginterferon for Hepatitis C",[86],"2006-03","2005-10",[21],[1761,3177],"peginterferon",{"trials":3179,"activeCount":97},[3180],{"nctId":1754,"briefTitle":1755,"status":119,"phases":3181,"completion":1757,"start":1758,"enrollment":113,"conditions":3182,"interventions":3183},[87],[21],[1761,1716,1762],{"trials":3185,"activeCount":97},[],{"trials":3187,"activeCount":97},[],{"trials":3189,"activeCount":97},[],{"intervention":3191,"totalTrials":137,"cells":3192},"VX-702",{"EARLY_PHASE1":3193,"PHASE1":3195,"PHASE2":3197,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3194,"activeCount":97},[],{"trials":3196,"activeCount":97},[],{"trials":3198,"activeCount":97},[3199,3207],{"nctId":3200,"briefTitle":3201,"status":119,"phases":3202,"completion":3203,"start":3204,"enrollment":810,"conditions":3205,"interventions":3206},"NCT00205478","Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702",[87],"2006-02","2005-06",[30],[3191],{"nctId":3208,"briefTitle":3209,"status":119,"phases":3210,"completion":3211,"start":3212,"enrollment":629,"conditions":3213,"interventions":3214},"NCT00395577","A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702",[87],"2007-07","2006-11",[30],[3191],{"trials":3216,"activeCount":97},[],{"trials":3218,"activeCount":97},[],{"trials":3220,"activeCount":97},[],{"intervention":3222,"totalTrials":137,"cells":3223},"VX-765",{"EARLY_PHASE1":3224,"PHASE1":3226,"PHASE2":3228,"PHASE3":3247,"PHASE4":3249,"NA":3251},{"trials":3225,"activeCount":97},[],{"trials":3227,"activeCount":97},[],{"trials":3229,"activeCount":97},[3230,3239],{"nctId":3231,"briefTitle":3232,"status":119,"phases":3233,"completion":3234,"start":3235,"enrollment":648,"conditions":3236,"interventions":3238},"NCT00205465","Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765",[87],"2005-09","2004-12",[3237],"Psoriasis",[3222],{"nctId":3240,"briefTitle":3241,"status":119,"phases":3242,"primaryCompletion":3243,"completion":3243,"start":1085,"enrollment":222,"conditions":3244,"interventions":3246},"NCT01048255","Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy",[87],"2010-11",[3245],"Partial Epilepsy",[3222],{"trials":3248,"activeCount":97},[],{"trials":3250,"activeCount":97},[],{"trials":3252,"activeCount":97},[],{"intervention":3254,"totalTrials":235,"cells":3255},"VX-814",{"EARLY_PHASE1":3256,"PHASE1":3258,"PHASE2":3260,"PHASE3":3271,"PHASE4":3273,"NA":3275},{"trials":3257,"activeCount":97},[],{"trials":3259,"activeCount":97},[],{"trials":3261,"activeCount":97},[3262],{"nctId":3263,"briefTitle":3264,"status":403,"phases":3265,"primaryCompletion":3266,"completion":3266,"start":3267,"enrollment":123,"conditions":3268,"interventions":3270},"NCT04167345","Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype",[87],"2020-11-14","2020-01-13",[3269],"Alpha 1-Antitrypsin Deficiency",[3254],{"trials":3272,"activeCount":97},[],{"trials":3274,"activeCount":97},[],{"trials":3276,"activeCount":97},[],{"intervention":3278,"totalTrials":235,"cells":3279},"biricodar dicitrate",{"EARLY_PHASE1":3280,"PHASE1":3282,"PHASE2":3284,"PHASE3":3297,"PHASE4":3299,"NA":3301},{"trials":3281,"activeCount":97},[],{"trials":3283,"activeCount":97},[],{"trials":3285,"activeCount":97},[3286],{"nctId":3287,"briefTitle":3288,"status":403,"phases":3289,"primaryCompletion":3290,"start":3291,"enrollment":2770,"conditions":3292,"interventions":3294},"NCT00003847","VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer",[87],"2001-02","1998-12",[3293],"Lung Cancer",[3278,3295,3296],"doxorubicin hydrochloride","vincristine sulfate",{"trials":3298,"activeCount":97},[],{"trials":3300,"activeCount":97},[],{"trials":3302,"activeCount":97},[],{"intervention":3295,"totalTrials":235,"cells":3304},{"EARLY_PHASE1":3305,"PHASE1":3307,"PHASE2":3309,"PHASE3":3315,"PHASE4":3317,"NA":3319},{"trials":3306,"activeCount":97},[],{"trials":3308,"activeCount":97},[],{"trials":3310,"activeCount":97},[3311],{"nctId":3287,"briefTitle":3288,"status":403,"phases":3312,"primaryCompletion":3290,"start":3291,"enrollment":2770,"conditions":3313,"interventions":3314},[87],[3293],[3278,3295,3296],{"trials":3316,"activeCount":97},[],{"trials":3318,"activeCount":97},[],{"trials":3320,"activeCount":97},[],{"intervention":3296,"totalTrials":235,"cells":3322},{"EARLY_PHASE1":3323,"PHASE1":3325,"PHASE2":3327,"PHASE3":3333,"PHASE4":3335,"NA":3337},{"trials":3324,"activeCount":97},[],{"trials":3326,"activeCount":97},[],{"trials":3328,"activeCount":97},[3329],{"nctId":3287,"briefTitle":3288,"status":403,"phases":3330,"primaryCompletion":3290,"start":3291,"enrollment":2770,"conditions":3331,"interventions":3332},[87],[3293],[3278,3295,3296],{"trials":3334,"activeCount":97},[],{"trials":3336,"activeCount":97},[],{"trials":3338,"activeCount":97},[],{"intervention":3119,"totalTrials":235,"cells":3340},{"EARLY_PHASE1":3341,"PHASE1":3343,"PHASE2":3345,"PHASE3":3351,"PHASE4":3353,"NA":3355},{"trials":3342,"activeCount":97},[],{"trials":3344,"activeCount":97},[],{"trials":3346,"activeCount":97},[3347],{"nctId":3112,"briefTitle":3113,"status":119,"phases":3348,"primaryCompletion":1890,"completion":1890,"start":1709,"enrollment":870,"conditions":3349,"interventions":3350},[87],[32,3116,3117,21],[1779,3119],{"trials":3352,"activeCount":97},[],{"trials":3354,"activeCount":97},[],{"trials":3356,"activeCount":97},[],{"intervention":3358,"totalTrials":235,"cells":3359},"VCH-759",{"EARLY_PHASE1":3360,"PHASE1":3362,"PHASE2":3364,"PHASE3":3373,"PHASE4":3375,"NA":3377},{"trials":3361,"activeCount":97},[],{"trials":3363,"activeCount":97},[],{"trials":3365,"activeCount":97},[3366],{"nctId":3367,"briefTitle":3368,"status":119,"phases":3369,"completion":3370,"start":1745,"enrollment":2770,"conditions":3371,"interventions":3372},"NCT00389298","A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.",[86,87],"2007-06",[1873],[3358],{"trials":3374,"activeCount":97},[],{"trials":3376,"activeCount":97},[],{"trials":3378,"activeCount":97},[],{"intervention":1751,"totalTrials":235,"cells":3380},{"EARLY_PHASE1":3381,"PHASE1":3383,"PHASE2":3385,"PHASE3":3391,"PHASE4":3393,"NA":3395},{"trials":3382,"activeCount":97},[],{"trials":3384,"activeCount":97},[],{"trials":3386,"activeCount":97},[3387],{"nctId":1742,"briefTitle":1743,"status":119,"phases":3388,"completion":1745,"start":1746,"enrollment":1747,"conditions":3389,"interventions":3390},[87],[21,1749],[1751,1752,1696],{"trials":3392,"activeCount":97},[],{"trials":3394,"activeCount":97},[],{"trials":3396,"activeCount":97},[],{"intervention":1752,"totalTrials":235,"cells":3398},{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3403,"PHASE3":3409,"PHASE4":3411,"NA":3413},{"trials":3400,"activeCount":97},[],{"trials":3402,"activeCount":97},[],{"trials":3404,"activeCount":97},[3405],{"nctId":1742,"briefTitle":1743,"status":119,"phases":3406,"completion":1745,"start":1746,"enrollment":1747,"conditions":3407,"interventions":3408},[87],[21,1749],[1751,1752,1696],{"trials":3410,"activeCount":97},[],{"trials":3412,"activeCount":97},[],{"trials":3414,"activeCount":97},[],{"intervention":371,"totalTrials":235,"cells":3416},{"EARLY_PHASE1":3417,"PHASE1":3419,"PHASE2":3421,"PHASE3":3427,"PHASE4":3429,"NA":3431},{"trials":3418,"activeCount":97},[],{"trials":3420,"activeCount":97},[],{"trials":3422,"activeCount":97},[3423],{"nctId":363,"briefTitle":364,"status":119,"phases":3424,"primaryCompletion":366,"completion":366,"start":367,"enrollment":368,"conditions":3425,"interventions":3426},[87],[15],[371,350,310],{"trials":3428,"activeCount":97},[],{"trials":3430,"activeCount":97},[],{"trials":3432,"activeCount":97},[],{"intervention":3434,"totalTrials":235,"cells":3435},"VX-787",{"EARLY_PHASE1":3436,"PHASE1":3438,"PHASE2":3440,"PHASE3":3451,"PHASE4":3453,"NA":3455},{"trials":3437,"activeCount":97},[],{"trials":3439,"activeCount":97},[],{"trials":3441,"activeCount":97},[3442],{"nctId":3443,"briefTitle":3444,"status":119,"phases":3445,"primaryCompletion":3446,"start":1830,"enrollment":3447,"conditions":3448,"interventions":3450},"NCT01561807","A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus",[87],"2012-10",140,[3449],"Influenza Virus",[3434],{"trials":3452,"activeCount":97},[],{"trials":3454,"activeCount":97},[],{"trials":3456,"activeCount":97},[],{"intervention":390,"totalTrials":235,"cells":3458},{"EARLY_PHASE1":3459,"PHASE1":3461,"PHASE2":3463,"PHASE3":3469,"PHASE4":3471,"NA":3473},{"trials":3460,"activeCount":97},[],{"trials":3462,"activeCount":97},[],{"trials":3464,"activeCount":97},[3465],{"nctId":382,"briefTitle":383,"status":119,"phases":3466,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":3467,"interventions":3468},[86,87],[15],[310,350,390,339,326,351,390],{"trials":3470,"activeCount":97},[],{"trials":3472,"activeCount":97},[],{"trials":3474,"activeCount":97},[],{"intervention":3476,"totalTrials":235,"cells":3477},"VX-765 Part A",{"EARLY_PHASE1":3478,"PHASE1":3480,"PHASE2":3482,"PHASE3":3493,"PHASE4":3495,"NA":3497},{"trials":3479,"activeCount":97},[],{"trials":3481,"activeCount":97},[],{"trials":3483,"activeCount":97},[3484],{"nctId":3485,"briefTitle":3486,"status":403,"phases":3487,"primaryCompletion":2100,"start":1860,"enrollment":3488,"conditions":3489,"interventions":3491},"NCT01501383","A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy",[87],55,[3490],"Epilepsy",[3476,3492],"VX-765 Part B",{"trials":3494,"activeCount":97},[],{"trials":3496,"activeCount":97},[],{"trials":3498,"activeCount":97},[],{"intervention":3492,"totalTrials":235,"cells":3500},{"EARLY_PHASE1":3501,"PHASE1":3503,"PHASE2":3505,"PHASE3":3511,"PHASE4":3513,"NA":3515},{"trials":3502,"activeCount":97},[],{"trials":3504,"activeCount":97},[],{"trials":3506,"activeCount":97},[3507],{"nctId":3485,"briefTitle":3486,"status":403,"phases":3508,"primaryCompletion":2100,"start":1860,"enrollment":3488,"conditions":3509,"interventions":3510},[87],[3490],[3476,3492],{"trials":3512,"activeCount":97},[],{"trials":3514,"activeCount":97},[],{"trials":3516,"activeCount":97},[],{"intervention":1807,"totalTrials":235,"cells":3518},{"EARLY_PHASE1":3519,"PHASE1":3521,"PHASE2":3523,"PHASE3":3529,"PHASE4":3531,"NA":3533},{"trials":3520,"activeCount":97},[],{"trials":3522,"activeCount":97},[],{"trials":3524,"activeCount":97},[3525],{"nctId":1801,"briefTitle":1802,"status":403,"phases":3526,"primaryCompletion":1804,"completion":1804,"start":1474,"enrollment":1210,"conditions":3527,"interventions":3528},[86,87],[21],[1727,1807,1696],{"trials":3530,"activeCount":97},[],{"trials":3532,"activeCount":97},[],{"trials":3534,"activeCount":97},[],{"intervention":1816,"totalTrials":235,"cells":3536},{"EARLY_PHASE1":3537,"PHASE1":3539,"PHASE2":3541,"PHASE3":3547,"PHASE4":3549,"NA":3551},{"trials":3538,"activeCount":97},[],{"trials":3540,"activeCount":97},[],{"trials":3542,"activeCount":97},[3543],{"nctId":1809,"briefTitle":1810,"status":403,"phases":3544,"primaryCompletion":1812,"completion":1812,"start":1767,"enrollment":638,"conditions":3545,"interventions":3546},[87],[21],[1727,1696,1815,1816],{"trials":3548,"activeCount":97},[],{"trials":3550,"activeCount":97},[],{"trials":3552,"activeCount":97},[],{"intervention":3554,"totalTrials":235,"cells":3555},"Cethrin",{"EARLY_PHASE1":3556,"PHASE1":3558,"PHASE2":3560,"PHASE3":3571,"PHASE4":3573,"NA":3575},{"trials":3557,"activeCount":97},[],{"trials":3559,"activeCount":97},[],{"trials":3561,"activeCount":97},[3562],{"nctId":3563,"briefTitle":3564,"status":119,"phases":3565,"primaryCompletion":1721,"completion":3566,"start":3567,"enrollment":123,"conditions":3568,"interventions":3570},"NCT00500812","A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries",[86,87],"2009-02","2005-02",[3569],"Spinal Cord Injury",[3554],{"trials":3572,"activeCount":97},[],{"trials":3574,"activeCount":97},[],{"trials":3576,"activeCount":97},[],{"intervention":3578,"totalTrials":235,"cells":3579},"Ivacaftor 25 mg\u002F75 mg",{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3596,"PHASE4":3598,"NA":3600},{"trials":3581,"activeCount":97},[],{"trials":3583,"activeCount":97},[],{"trials":3585,"activeCount":97},[3586],{"nctId":3587,"briefTitle":3588,"status":119,"phases":3589,"primaryCompletion":3590,"completion":3590,"start":3591,"enrollment":1241,"conditions":3592,"interventions":3593},"NCT00457821","Safety Study of Ivacaftor in Subjects With Cystic Fibrosis",[87],"2008-08","2007-05",[15],[3578,3594,3595],"Ivacaftor 75 mg\u002F150 mg","Ivacaftor 150 mg or 250 mg",{"trials":3597,"activeCount":97},[],{"trials":3599,"activeCount":97},[],{"trials":3601,"activeCount":97},[],{"intervention":3594,"totalTrials":235,"cells":3603},{"EARLY_PHASE1":3604,"PHASE1":3606,"PHASE2":3608,"PHASE3":3614,"PHASE4":3616,"NA":3618},{"trials":3605,"activeCount":97},[],{"trials":3607,"activeCount":97},[],{"trials":3609,"activeCount":97},[3610],{"nctId":3587,"briefTitle":3588,"status":119,"phases":3611,"primaryCompletion":3590,"completion":3590,"start":3591,"enrollment":1241,"conditions":3612,"interventions":3613},[87],[15],[3578,3594,3595],{"trials":3615,"activeCount":97},[],{"trials":3617,"activeCount":97},[],{"trials":3619,"activeCount":97},[],{"intervention":3595,"totalTrials":235,"cells":3621},{"EARLY_PHASE1":3622,"PHASE1":3624,"PHASE2":3626,"PHASE3":3632,"PHASE4":3634,"NA":3636},{"trials":3623,"activeCount":97},[],{"trials":3625,"activeCount":97},[],{"trials":3627,"activeCount":97},[3628],{"nctId":3587,"briefTitle":3588,"status":119,"phases":3629,"primaryCompletion":3590,"completion":3590,"start":3591,"enrollment":1241,"conditions":3630,"interventions":3631},[87],[15],[3578,3594,3595],{"trials":3633,"activeCount":97},[],{"trials":3635,"activeCount":97},[],{"trials":3637,"activeCount":97},[],{"intervention":1480,"totalTrials":203,"cells":3639},{"EARLY_PHASE1":3640,"PHASE1":3642,"PHASE2":3660,"PHASE3":3662,"PHASE4":3664,"NA":3666},{"trials":3641,"activeCount":97},[],{"trials":3643,"activeCount":97},[3644,3648,3656],{"nctId":1470,"briefTitle":1471,"status":119,"phases":3645,"primaryCompletion":1473,"start":1474,"enrollment":368,"conditions":3646,"interventions":3647},[86],[15],[1477,1478,1479,1214,1480],{"nctId":3649,"briefTitle":3650,"status":119,"phases":3651,"primaryCompletion":3652,"completion":3652,"start":3653,"enrollment":1201,"conditions":3654,"interventions":3655},"NCT01018368","Study of VX-770 and Rifampin in Healthy Male Subjects",[86],"2010-03","2009-11",[15],[2380,1480],{"nctId":2774,"briefTitle":2775,"status":119,"phases":3657,"primaryCompletion":2777,"completion":2777,"start":2778,"enrollment":1231,"conditions":3658,"interventions":3659},[86],[18],[1255,2781,1480],{"trials":3661,"activeCount":97},[],{"trials":3663,"activeCount":97},[],{"trials":3665,"activeCount":97},[],{"trials":3667,"activeCount":97},[],{"intervention":1414,"totalTrials":137,"cells":3669},{"EARLY_PHASE1":3670,"PHASE1":3672,"PHASE2":3686,"PHASE3":3688,"PHASE4":3690,"NA":3692},{"trials":3671,"activeCount":97},[],{"trials":3673,"activeCount":97},[3674,3682],{"nctId":3675,"briefTitle":3676,"status":119,"phases":3677,"primaryCompletion":3678,"completion":3678,"start":3679,"enrollment":849,"conditions":3680,"interventions":3681},"NCT06615570","A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants",[86],"2025-07-21","2024-09-30",[18],[1414],{"nctId":1407,"briefTitle":1408,"status":119,"phases":3683,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":849,"conditions":3684,"interventions":3685},[86],[18],[1414,1215],{"trials":3687,"activeCount":97},[],{"trials":3689,"activeCount":97},[],{"trials":3691,"activeCount":97},[],{"trials":3693,"activeCount":97},[],{"intervention":1479,"totalTrials":137,"cells":3695},{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3708,"PHASE3":3710,"PHASE4":3712,"NA":3714},{"trials":3697,"activeCount":97},[],{"trials":3699,"activeCount":97},[3700,3704],{"nctId":1470,"briefTitle":1471,"status":119,"phases":3701,"primaryCompletion":1473,"start":1474,"enrollment":368,"conditions":3702,"interventions":3703},[86],[15],[1477,1478,1479,1214,1480],{"nctId":2943,"briefTitle":2944,"status":119,"phases":3705,"primaryCompletion":1775,"completion":1775,"start":1869,"enrollment":989,"conditions":3706,"interventions":3707},[86],[15],[2106,2936,2948],{"trials":3709,"activeCount":97},[],{"trials":3711,"activeCount":97},[],{"trials":3713,"activeCount":97},[],{"trials":3715,"activeCount":97},[],{"intervention":1405,"totalTrials":137,"cells":3717},{"EARLY_PHASE1":3718,"PHASE1":3720,"PHASE2":3734,"PHASE3":3736,"PHASE4":3738,"NA":3740},{"trials":3719,"activeCount":97},[],{"trials":3721,"activeCount":97},[3722,3726],{"nctId":1398,"briefTitle":1399,"status":119,"phases":3723,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":648,"conditions":3724,"interventions":3725},[86],[18],[1405,1214,1215],{"nctId":3727,"briefTitle":3728,"status":119,"phases":3729,"primaryCompletion":3730,"completion":3730,"start":3731,"enrollment":232,"conditions":3732,"interventions":3733},"NCT05347394","A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants",[86],"2023-04-14","2022-04-08",[24],[1405],{"trials":3735,"activeCount":97},[],{"trials":3737,"activeCount":97},[],{"trials":3739,"activeCount":97},[],{"trials":3741,"activeCount":97},[],{"intervention":3743,"totalTrials":137,"cells":3744},"IXP",{"EARLY_PHASE1":3745,"PHASE1":3747,"PHASE2":3764,"PHASE3":3766,"PHASE4":3768,"NA":3770},{"trials":3746,"activeCount":97},[],{"trials":3748,"activeCount":97},[3749,3756],{"nctId":3750,"briefTitle":3751,"status":119,"phases":3752,"primaryCompletion":1239,"completion":1239,"start":2752,"enrollment":251,"conditions":3753,"interventions":3755},"NCT05865171","A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment",[86],[3754],"Renal Impairment",[3743],{"nctId":3757,"briefTitle":3758,"status":119,"phases":3759,"primaryCompletion":3760,"completion":3760,"start":3761,"enrollment":2770,"conditions":3762,"interventions":3763},"NCT06529796","Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment",[86],"2024-12-20","2024-08-02",[1042],[3743],{"trials":3765,"activeCount":97},[],{"trials":3767,"activeCount":97},[],{"trials":3769,"activeCount":97},[],{"trials":3771,"activeCount":97},[],{"intervention":2757,"totalTrials":137,"cells":3773},{"EARLY_PHASE1":3774,"PHASE1":3776,"PHASE2":3793,"PHASE3":3795,"PHASE4":3797,"NA":3799},{"trials":3775,"activeCount":97},[],{"trials":3777,"activeCount":97},[3778,3789],{"nctId":3779,"briefTitle":3780,"status":119,"phases":3781,"primaryCompletion":3782,"completion":3782,"start":3783,"enrollment":3784,"conditions":3785,"interventions":3786},"NCT05867147","An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT\u002FQTc Interval in Healthy Participants",[86],"2023-06-14","2023-04-26",56,[15],[3787,3788,2757,2758],"Vanzacaftor","Vanzacaftor Placebo",{"nctId":2749,"briefTitle":2750,"status":119,"phases":3790,"primaryCompletion":2752,"completion":2753,"start":2754,"enrollment":2187,"conditions":3791,"interventions":3792},[86],[18],[1255,2757,2758,2759],{"trials":3794,"activeCount":97},[],{"trials":3796,"activeCount":97},[],{"trials":3798,"activeCount":97},[],{"trials":3800,"activeCount":97},[],{"intervention":2758,"totalTrials":137,"cells":3802},{"EARLY_PHASE1":3803,"PHASE1":3805,"PHASE2":3815,"PHASE3":3817,"PHASE4":3819,"NA":3821},{"trials":3804,"activeCount":97},[],{"trials":3806,"activeCount":97},[3807,3811],{"nctId":3779,"briefTitle":3780,"status":119,"phases":3808,"primaryCompletion":3782,"completion":3782,"start":3783,"enrollment":3784,"conditions":3809,"interventions":3810},[86],[15],[3787,3788,2757,2758],{"nctId":2749,"briefTitle":2750,"status":119,"phases":3812,"primaryCompletion":2752,"completion":2753,"start":2754,"enrollment":2187,"conditions":3813,"interventions":3814},[86],[18],[1255,2757,2758,2759],{"trials":3816,"activeCount":97},[],{"trials":3818,"activeCount":97},[],{"trials":3820,"activeCount":97},[],{"trials":3822,"activeCount":97},[],{"intervention":136,"totalTrials":137,"cells":3824},{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3837,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3826,"activeCount":97},[],{"trials":3828,"activeCount":97},[3829,3833],{"nctId":1293,"briefTitle":1294,"status":119,"phases":3830,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":336,"conditions":3831,"interventions":3832},[86],[34],[1278,1301,136,1302,135],{"nctId":127,"briefTitle":128,"status":119,"phases":3834,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":3835,"interventions":3836},[86],[18],[58,135,136],{"trials":3838,"activeCount":97},[],{"trials":3840,"activeCount":97},[],{"trials":3842,"activeCount":97},[],{"trials":3844,"activeCount":97},[],{"intervention":135,"totalTrials":137,"cells":3846},{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3859,"PHASE3":3861,"PHASE4":3863,"NA":3865},{"trials":3848,"activeCount":97},[],{"trials":3850,"activeCount":97},[3851,3855],{"nctId":1293,"briefTitle":1294,"status":119,"phases":3852,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":336,"conditions":3853,"interventions":3854},[86],[34],[1278,1301,136,1302,135],{"nctId":127,"briefTitle":128,"status":119,"phases":3856,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":3857,"interventions":3858},[86],[18],[58,135,136],{"trials":3860,"activeCount":97},[],{"trials":3862,"activeCount":97},[],{"trials":3864,"activeCount":97},[],{"trials":3866,"activeCount":97},[],{"intervention":2091,"totalTrials":235,"cells":3868},{"EARLY_PHASE1":3869,"PHASE1":3871,"PHASE2":3877,"PHASE3":3879,"PHASE4":3881,"NA":3883},{"trials":3870,"activeCount":97},[],{"trials":3872,"activeCount":97},[3873],{"nctId":2082,"briefTitle":2083,"status":119,"phases":3874,"primaryCompletion":2085,"completion":2085,"start":1709,"enrollment":2086,"conditions":3875,"interventions":3876},[86],[15],[1477,2089,1478,2090,2091],{"trials":3878,"activeCount":97},[],{"trials":3880,"activeCount":97},[],{"trials":3882,"activeCount":97},[],{"trials":3884,"activeCount":97},[],{"intervention":327,"totalTrials":235,"cells":3886},{"EARLY_PHASE1":3887,"PHASE1":3889,"PHASE2":3895,"PHASE3":3897,"PHASE4":3899,"NA":3901},{"trials":3888,"activeCount":97},[],{"trials":3890,"activeCount":97},[3891],{"nctId":318,"briefTitle":319,"status":119,"phases":3892,"primaryCompletion":321,"completion":321,"start":322,"enrollment":251,"conditions":3893,"interventions":3894},[86],[15],[325,326,310,327],{"trials":3896,"activeCount":97},[],{"trials":3898,"activeCount":97},[],{"trials":3900,"activeCount":97},[],{"trials":3902,"activeCount":97},[],{"intervention":3904,"totalTrials":235,"cells":3905},"lumacaftor 200 mg q12h + ivacaftor 250 mg q12h",{"EARLY_PHASE1":3906,"PHASE1":3908,"PHASE2":3917,"PHASE3":3919,"PHASE4":3921,"NA":3923},{"trials":3907,"activeCount":97},[],{"trials":3909,"activeCount":97},[3910],{"nctId":3911,"briefTitle":3912,"status":119,"phases":3913,"primaryCompletion":1734,"completion":1734,"start":1709,"enrollment":870,"conditions":3914,"interventions":3916},"NCT01888393","Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects",[86],[3915,2189],"Hepatic Impairment",[3904],{"trials":3918,"activeCount":97},[],{"trials":3920,"activeCount":97},[],{"trials":3922,"activeCount":97},[],{"trials":3924,"activeCount":97},[],{"intervention":3926,"totalTrials":235,"cells":3927},"VCH-222",{"EARLY_PHASE1":3928,"PHASE1":3930,"PHASE2":3939,"PHASE3":3941,"PHASE4":3943,"NA":3945},{"trials":3929,"activeCount":97},[],{"trials":3931,"activeCount":97},[3932],{"nctId":3933,"briefTitle":3934,"status":119,"phases":3935,"primaryCompletion":1085,"completion":1085,"start":3936,"enrollment":849,"conditions":3937,"interventions":3938},"NCT00958152","Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects",[86],"2009-08",[21],[3926,3926,3926,1089],{"trials":3940,"activeCount":97},[],{"trials":3942,"activeCount":97},[],{"trials":3944,"activeCount":97},[],{"trials":3946,"activeCount":97},[],{"intervention":3948,"totalTrials":235,"cells":3949},"14C-VX-993",{"EARLY_PHASE1":3950,"PHASE1":3952,"PHASE2":3961,"PHASE3":3963,"PHASE4":3965,"NA":3967},{"trials":3951,"activeCount":97},[],{"trials":3953,"activeCount":97},[3954],{"nctId":3955,"briefTitle":3956,"status":119,"phases":3957,"primaryCompletion":3958,"completion":3958,"start":231,"enrollment":1898,"conditions":3959,"interventions":3960},"NCT06886269","A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose",[86],"2025-05-17",[18],[3948],{"trials":3962,"activeCount":97},[],{"trials":3964,"activeCount":97},[],{"trials":3966,"activeCount":97},[],{"trials":3968,"activeCount":97},[],{"intervention":3970,"totalTrials":235,"cells":3971},"AVN-944 capsules for oral administration",{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3989,"PHASE3":3991,"PHASE4":3993,"NA":3995},{"trials":3973,"activeCount":97},[],{"trials":3975,"activeCount":97},[3976],{"nctId":3977,"briefTitle":3978,"status":119,"phases":3979,"start":3980,"enrollment":2187,"conditions":3981,"interventions":3988},"NCT00273936","Trial of AVN-944 in Patients With Advanced Hematologic Malignancies",[86],"2006-01",[3982,3983,3984,3985,3986,3987],"Acute Leukemia","Chronic Leukemia","Multiple Myeloma","Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma","Waldenstrom's Macroglobulinemia",[3970],{"trials":3990,"activeCount":97},[],{"trials":3992,"activeCount":97},[],{"trials":3994,"activeCount":97},[],{"trials":3996,"activeCount":97},[],{"intervention":2381,"totalTrials":235,"cells":3998},{"EARLY_PHASE1":3999,"PHASE1":4001,"PHASE2":4007,"PHASE3":4009,"PHASE4":4011,"NA":4013},{"trials":4000,"activeCount":97},[],{"trials":4002,"activeCount":97},[4003],{"nctId":2373,"briefTitle":2374,"status":119,"phases":4004,"primaryCompletion":2376,"completion":2376,"start":2377,"enrollment":1201,"conditions":4005,"interventions":4006},[86],[15],[2366,2380,2381],{"trials":4008,"activeCount":97},[],{"trials":4010,"activeCount":97},[],{"trials":4012,"activeCount":97},[],{"trials":4014,"activeCount":97},[],{"intervention":4016,"totalTrials":235,"cells":4017},"VX-840",{"EARLY_PHASE1":4018,"PHASE1":4020,"PHASE2":4031,"PHASE3":4033,"PHASE4":4035,"NA":4037},{"trials":4019,"activeCount":97},[],{"trials":4021,"activeCount":97},[4022],{"nctId":4023,"briefTitle":4024,"status":119,"phases":4025,"primaryCompletion":4026,"completion":4026,"start":4027,"enrollment":1222,"conditions":4028,"interventions":4030},"NCT05324410","A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants",[86],"2022-11-07","2022-04-07",[4029],"APOL1-mediated Kidney Disease",[4016],{"trials":4032,"activeCount":97},[],{"trials":4034,"activeCount":97},[],{"trials":4036,"activeCount":97},[],{"trials":4038,"activeCount":97},[],{"intervention":4040,"totalTrials":235,"cells":4041},"VCH 916",{"EARLY_PHASE1":4042,"PHASE1":4044,"PHASE2":4054,"PHASE3":4056,"PHASE4":4058,"NA":4060},{"trials":4043,"activeCount":97},[],{"trials":4045,"activeCount":97},[4046],{"nctId":4047,"briefTitle":4048,"status":119,"phases":4049,"primaryCompletion":1852,"completion":1852,"start":4050,"enrollment":1210,"conditions":4051,"interventions":4053},"NCT00623649","Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection",[86],"2007-11",[4052],"HCV Infection",[4040],{"trials":4055,"activeCount":97},[],{"trials":4057,"activeCount":97},[],{"trials":4059,"activeCount":97},[],{"trials":4061,"activeCount":97},[],{"intervention":3787,"totalTrials":235,"cells":4063},{"EARLY_PHASE1":4064,"PHASE1":4066,"PHASE2":4072,"PHASE3":4074,"PHASE4":4076,"NA":4078},{"trials":4065,"activeCount":97},[],{"trials":4067,"activeCount":97},[4068],{"nctId":3779,"briefTitle":3780,"status":119,"phases":4069,"primaryCompletion":3782,"completion":3782,"start":3783,"enrollment":3784,"conditions":4070,"interventions":4071},[86],[15],[3787,3788,2757,2758],{"trials":4073,"activeCount":97},[],{"trials":4075,"activeCount":97},[],{"trials":4077,"activeCount":97},[],{"trials":4079,"activeCount":97},[],{"intervention":3788,"totalTrials":235,"cells":4081},{"EARLY_PHASE1":4082,"PHASE1":4084,"PHASE2":4090,"PHASE3":4092,"PHASE4":4094,"NA":4096},{"trials":4083,"activeCount":97},[],{"trials":4085,"activeCount":97},[4086],{"nctId":3779,"briefTitle":3780,"status":119,"phases":4087,"primaryCompletion":3782,"completion":3782,"start":3783,"enrollment":3784,"conditions":4088,"interventions":4089},[86],[15],[3787,3788,2757,2758],{"trials":4091,"activeCount":97},[],{"trials":4093,"activeCount":97},[],{"trials":4095,"activeCount":97},[],{"trials":4097,"activeCount":97},[],{"intervention":4099,"totalTrials":235,"cells":4100},"buprenorphine\u002Fnaloxone",{"EARLY_PHASE1":4101,"PHASE1":4103,"PHASE2":4114,"PHASE3":4116,"PHASE4":4118,"NA":4120},{"trials":4102,"activeCount":97},[],{"trials":4104,"activeCount":97},[4105],{"nctId":4106,"briefTitle":4107,"status":119,"phases":4108,"primaryCompletion":4109,"start":4110,"enrollment":251,"conditions":4111,"interventions":4113},"NCT01275599","Drug-Drug Interaction Study Between Telaprevir and Buprenorphine",[86],"2011-04","2011-01",[21,4112],"Opioid-Related Disorders",[1089,4099],{"trials":4115,"activeCount":97},[],{"trials":4117,"activeCount":97},[],{"trials":4119,"activeCount":97},[],{"trials":4121,"activeCount":97},[],{"intervention":1090,"totalTrials":235,"cells":4123},{"EARLY_PHASE1":4124,"PHASE1":4126,"PHASE2":4132,"PHASE3":4134,"PHASE4":4136,"NA":4138},{"trials":4125,"activeCount":97},[],{"trials":4127,"activeCount":97},[4128],{"nctId":1081,"briefTitle":1082,"status":119,"phases":4129,"primaryCompletion":1084,"completion":1084,"start":1085,"enrollment":1086,"conditions":4130,"interventions":4131},[86],[21],[1089,1089,1090,1090,1074,1074],{"trials":4133,"activeCount":97},[],{"trials":4135,"activeCount":97},[],{"trials":4137,"activeCount":97},[],{"trials":4139,"activeCount":97},[],{"intervention":4141,"totalTrials":235,"cells":4142},"VX-634",{"EARLY_PHASE1":4143,"PHASE1":4145,"PHASE2":4157,"PHASE3":4159,"PHASE4":4161,"NA":4163},{"trials":4144,"activeCount":97},[],{"trials":4146,"activeCount":97},[4147],{"nctId":4148,"briefTitle":4149,"status":119,"phases":4150,"primaryCompletion":4151,"completion":4152,"start":4153,"enrollment":4154,"conditions":4155,"interventions":4156},"NCT05579431","A Phase 1, First-in-human Study of VX-634",[86],"2023-05-24","2023-11-13","2022-10-13",127,[3269],[4141],{"trials":4158,"activeCount":97},[],{"trials":4160,"activeCount":97},[],{"trials":4162,"activeCount":97},[],{"trials":4164,"activeCount":97},[],{"intervention":2759,"totalTrials":235,"cells":4166},{"EARLY_PHASE1":4167,"PHASE1":4169,"PHASE2":4175,"PHASE3":4177,"PHASE4":4179,"NA":4181},{"trials":4168,"activeCount":97},[],{"trials":4170,"activeCount":97},[4171],{"nctId":2749,"briefTitle":2750,"status":119,"phases":4172,"primaryCompletion":2752,"completion":2753,"start":2754,"enrollment":2187,"conditions":4173,"interventions":4174},[86],[18],[1255,2757,2758,2759],{"trials":4176,"activeCount":97},[],{"trials":4178,"activeCount":97},[],{"trials":4180,"activeCount":97},[],{"trials":4182,"activeCount":97},[],{"intervention":2389,"totalTrials":235,"cells":4184},{"EARLY_PHASE1":4185,"PHASE1":4187,"PHASE2":4193,"PHASE3":4195,"PHASE4":4197,"NA":4199},{"trials":4186,"activeCount":97},[],{"trials":4188,"activeCount":97},[4189],{"nctId":2383,"briefTitle":2384,"status":119,"phases":4190,"primaryCompletion":2386,"completion":2386,"start":2113,"enrollment":123,"conditions":4191,"interventions":4192},[86],[15],[2366,2380,2389,2390],{"trials":4194,"activeCount":97},[],{"trials":4196,"activeCount":97},[],{"trials":4198,"activeCount":97},[],{"trials":4200,"activeCount":97},[],{"intervention":2390,"totalTrials":235,"cells":4202},{"EARLY_PHASE1":4203,"PHASE1":4205,"PHASE2":4211,"PHASE3":4213,"PHASE4":4215,"NA":4217},{"trials":4204,"activeCount":97},[],{"trials":4206,"activeCount":97},[4207],{"nctId":2383,"briefTitle":2384,"status":119,"phases":4208,"primaryCompletion":2386,"completion":2386,"start":2113,"enrollment":123,"conditions":4209,"interventions":4210},[86],[15],[2366,2380,2389,2390],{"trials":4212,"activeCount":97},[],{"trials":4214,"activeCount":97},[],{"trials":4216,"activeCount":97},[],{"trials":4218,"activeCount":97},[],{"intervention":1213,"totalTrials":235,"cells":4220},{"EARLY_PHASE1":4221,"PHASE1":4223,"PHASE2":4229,"PHASE3":4231,"PHASE4":4233,"NA":4235},{"trials":4222,"activeCount":97},[],{"trials":4224,"activeCount":97},[4225],{"nctId":1205,"briefTitle":1206,"status":119,"phases":4226,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":1210,"conditions":4227,"interventions":4228},[86],[18],[813,1213,1214,1215],{"trials":4230,"activeCount":97},[],{"trials":4232,"activeCount":97},[],{"trials":4234,"activeCount":97},[],{"trials":4236,"activeCount":97},[],{"intervention":1009,"totalTrials":235,"cells":4238},{"EARLY_PHASE1":4239,"PHASE1":4241,"PHASE2":4247,"PHASE3":4249,"PHASE4":4251,"NA":4253},{"trials":4240,"activeCount":97},[],{"trials":4242,"activeCount":97},[4243],{"nctId":1001,"briefTitle":1002,"status":119,"phases":4244,"primaryCompletion":1004,"completion":1005,"start":1006,"enrollment":22,"conditions":4245,"interventions":4246},[86],[15],[977,1009],{"trials":4248,"activeCount":97},[],{"trials":4250,"activeCount":97},[],{"trials":4252,"activeCount":97},[],{"trials":4254,"activeCount":97},[],{"intervention":1429,"totalTrials":235,"cells":4256},{"EARLY_PHASE1":4257,"PHASE1":4259,"PHASE2":4265,"PHASE3":4267,"PHASE4":4269,"NA":4271},{"trials":4258,"activeCount":97},[],{"trials":4260,"activeCount":97},[4261],{"nctId":1420,"briefTitle":1421,"status":119,"phases":4262,"primaryCompletion":1423,"completion":1424,"start":1425,"enrollment":1426,"conditions":4263,"interventions":4264},[86],[18],[1255,1215,1429],{"trials":4266,"activeCount":97},[],{"trials":4268,"activeCount":97},[],{"trials":4270,"activeCount":97},[],{"trials":4272,"activeCount":97},[],{"intervention":4274,"totalTrials":235,"cells":4275},"VX-668",{"EARLY_PHASE1":4276,"PHASE1":4278,"PHASE2":4289,"PHASE3":4291,"PHASE4":4293,"NA":4295},{"trials":4277,"activeCount":97},[],{"trials":4279,"activeCount":97},[4280],{"nctId":4281,"briefTitle":4282,"status":119,"phases":4283,"primaryCompletion":1192,"completion":4284,"start":4285,"enrollment":4286,"conditions":4287,"interventions":4288},"NCT05727800","A Phase 1, First-in-human Study of VX-668",[86],"2024-02-13","2023-02-08",114,[3147],[4274],{"trials":4290,"activeCount":97},[],{"trials":4292,"activeCount":97},[],{"trials":4294,"activeCount":97},[],{"trials":4296,"activeCount":97},[],{"intervention":4298,"totalTrials":235,"cells":4299},"telaprevir formulation A",{"EARLY_PHASE1":4300,"PHASE1":4302,"PHASE2":4314,"PHASE3":4316,"PHASE4":4318,"NA":4320},{"trials":4301,"activeCount":97},[],{"trials":4303,"activeCount":97},[4304],{"nctId":4305,"briefTitle":4306,"status":119,"phases":4307,"primaryCompletion":4308,"completion":1711,"start":1891,"enrollment":648,"conditions":4309,"interventions":4310},"NCT01511432","A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects",[86],"2012-06",[32],[4298,4311,4312,4313],"telaprevir Formulation B","telaprevir Formulation C","telaprevir Formulation D",{"trials":4315,"activeCount":97},[],{"trials":4317,"activeCount":97},[],{"trials":4319,"activeCount":97},[],{"trials":4321,"activeCount":97},[],{"intervention":4311,"totalTrials":235,"cells":4323},{"EARLY_PHASE1":4324,"PHASE1":4326,"PHASE2":4332,"PHASE3":4334,"PHASE4":4336,"NA":4338},{"trials":4325,"activeCount":97},[],{"trials":4327,"activeCount":97},[4328],{"nctId":4305,"briefTitle":4306,"status":119,"phases":4329,"primaryCompletion":4308,"completion":1711,"start":1891,"enrollment":648,"conditions":4330,"interventions":4331},[86],[32],[4298,4311,4312,4313],{"trials":4333,"activeCount":97},[],{"trials":4335,"activeCount":97},[],{"trials":4337,"activeCount":97},[],{"trials":4339,"activeCount":97},[],{"intervention":4312,"totalTrials":235,"cells":4341},{"EARLY_PHASE1":4342,"PHASE1":4344,"PHASE2":4350,"PHASE3":4352,"PHASE4":4354,"NA":4356},{"trials":4343,"activeCount":97},[],{"trials":4345,"activeCount":97},[4346],{"nctId":4305,"briefTitle":4306,"status":119,"phases":4347,"primaryCompletion":4308,"completion":1711,"start":1891,"enrollment":648,"conditions":4348,"interventions":4349},[86],[32],[4298,4311,4312,4313],{"trials":4351,"activeCount":97},[],{"trials":4353,"activeCount":97},[],{"trials":4355,"activeCount":97},[],{"trials":4357,"activeCount":97},[],{"intervention":4313,"totalTrials":235,"cells":4359},{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4368,"PHASE3":4370,"PHASE4":4372,"NA":4374},{"trials":4361,"activeCount":97},[],{"trials":4363,"activeCount":97},[4364],{"nctId":4305,"briefTitle":4306,"status":119,"phases":4365,"primaryCompletion":4308,"completion":1711,"start":1891,"enrollment":648,"conditions":4366,"interventions":4367},[86],[32],[4298,4311,4312,4313],{"trials":4369,"activeCount":97},[],{"trials":4371,"activeCount":97},[],{"trials":4373,"activeCount":97},[],{"trials":4375,"activeCount":97},[],{"intervention":1301,"totalTrials":235,"cells":4377},{"EARLY_PHASE1":4378,"PHASE1":4380,"PHASE2":4386,"PHASE3":4388,"PHASE4":4390,"NA":4392},{"trials":4379,"activeCount":97},[],{"trials":4381,"activeCount":97},[4382],{"nctId":1293,"briefTitle":1294,"status":119,"phases":4383,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":336,"conditions":4384,"interventions":4385},[86],[34],[1278,1301,136,1302,135],{"trials":4387,"activeCount":97},[],{"trials":4389,"activeCount":97},[],{"trials":4391,"activeCount":97},[],{"trials":4393,"activeCount":97},[],{"intervention":1302,"totalTrials":235,"cells":4395},{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4404,"PHASE3":4406,"PHASE4":4408,"NA":4410},{"trials":4397,"activeCount":97},[],{"trials":4399,"activeCount":97},[4400],{"nctId":1293,"briefTitle":1294,"status":119,"phases":4401,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":336,"conditions":4402,"interventions":4403},[86],[34],[1278,1301,136,1302,135],{"trials":4405,"activeCount":97},[],{"trials":4407,"activeCount":97},[],{"trials":4409,"activeCount":97},[],{"trials":4411,"activeCount":97},[],{"intervention":1234,"totalTrials":235,"cells":4413},{"EARLY_PHASE1":4414,"PHASE1":4416,"PHASE2":4422,"PHASE3":4424,"PHASE4":4426,"NA":4428},{"trials":4415,"activeCount":97},[],{"trials":4417,"activeCount":97},[4418],{"nctId":1226,"briefTitle":1227,"status":119,"phases":4419,"primaryCompletion":1229,"completion":1229,"start":1230,"enrollment":1231,"conditions":4420,"interventions":4421},[86],[18],[813,1234],{"trials":4423,"activeCount":97},[],{"trials":4425,"activeCount":97},[],{"trials":4427,"activeCount":97},[],{"trials":4429,"activeCount":97},[],{"intervention":2781,"totalTrials":235,"cells":4431},{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4440,"PHASE3":4442,"PHASE4":4444,"NA":4446},{"trials":4433,"activeCount":97},[],{"trials":4435,"activeCount":97},[4436],{"nctId":2774,"briefTitle":2775,"status":119,"phases":4437,"primaryCompletion":2777,"completion":2777,"start":2778,"enrollment":1231,"conditions":4438,"interventions":4439},[86],[18],[1255,2781,1480],{"trials":4441,"activeCount":97},[],{"trials":4443,"activeCount":97},[],{"trials":4445,"activeCount":97},[],{"trials":4447,"activeCount":97},[],{"intervention":3177,"totalTrials":235,"cells":4449},{"EARLY_PHASE1":4450,"PHASE1":4452,"PHASE2":4458,"PHASE3":4460,"PHASE4":4462,"NA":4464},{"trials":4451,"activeCount":97},[],{"trials":4453,"activeCount":97},[4454],{"nctId":3170,"briefTitle":3171,"status":119,"phases":4455,"completion":3173,"start":3174,"enrollment":1086,"conditions":4456,"interventions":4457},[86],[21],[1761,3177],{"trials":4459,"activeCount":97},[],{"trials":4461,"activeCount":97},[],{"trials":4463,"activeCount":97},[],{"trials":4465,"activeCount":97},[],{"intervention":2198,"totalTrials":235,"cells":4467},{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4476,"PHASE3":4478,"PHASE4":4480,"NA":4482},{"trials":4469,"activeCount":97},[],{"trials":4471,"activeCount":97},[4472],{"nctId":2192,"briefTitle":2193,"status":119,"phases":4473,"primaryCompletion":2100,"completion":2100,"start":1709,"enrollment":2102,"conditions":4474,"interventions":4475},[86],[2196],[2198,2177,2199],{"trials":4477,"activeCount":97},[],{"trials":4479,"activeCount":97},[],{"trials":4481,"activeCount":97},[],{"trials":4483,"activeCount":97},[],{"intervention":2199,"totalTrials":235,"cells":4485},{"EARLY_PHASE1":4486,"PHASE1":4488,"PHASE2":4494,"PHASE3":4496,"PHASE4":4498,"NA":4500},{"trials":4487,"activeCount":97},[],{"trials":4489,"activeCount":97},[4490],{"nctId":2192,"briefTitle":2193,"status":119,"phases":4491,"primaryCompletion":2100,"completion":2100,"start":1709,"enrollment":2102,"conditions":4492,"interventions":4493},[86],[2196],[2198,2177,2199],{"trials":4495,"activeCount":97},[],{"trials":4497,"activeCount":97},[],{"trials":4499,"activeCount":97},[],{"trials":4501,"activeCount":97},[],{"intervention":1478,"totalTrials":989,"cells":4503},{"EARLY_PHASE1":4504,"PHASE1":4506,"PHASE2":4528,"PHASE3":4577,"PHASE4":4697,"NA":4699},{"trials":4505,"activeCount":97},[],{"trials":4507,"activeCount":97},[4508,4512,4516,4520,4524],{"nctId":2082,"briefTitle":2083,"status":119,"phases":4509,"primaryCompletion":2085,"completion":2085,"start":1709,"enrollment":2086,"conditions":4510,"interventions":4511},[86],[15],[1477,2089,1478,2090,2091],{"nctId":1470,"briefTitle":1471,"status":119,"phases":4513,"primaryCompletion":1473,"start":1474,"enrollment":368,"conditions":4514,"interventions":4515},[86],[15],[1477,1478,1479,1214,1480],{"nctId":1508,"briefTitle":1509,"status":119,"phases":4517,"primaryCompletion":334,"completion":334,"start":367,"enrollment":1511,"conditions":4518,"interventions":4519},[86],[15],[349,1448,1478],{"nctId":2943,"briefTitle":2944,"status":119,"phases":4521,"primaryCompletion":1775,"completion":1775,"start":1869,"enrollment":989,"conditions":4522,"interventions":4523},[86],[15],[2106,2936,2948],{"nctId":2097,"briefTitle":2098,"status":119,"phases":4525,"primaryCompletion":2100,"completion":2100,"start":2101,"enrollment":2102,"conditions":4526,"interventions":4527},[86],[15],[2105,2106],{"trials":4529,"activeCount":97},[4530,4536,4542,4546,4552,4561,4569,4573],{"nctId":4531,"briefTitle":4532,"status":119,"phases":4533,"primaryCompletion":1870,"completion":1870,"start":4110,"enrollment":1040,"conditions":4534,"interventions":4535},"NCT01262352","Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation",[87],[15],[1478],{"nctId":4537,"briefTitle":4538,"status":403,"phases":4539,"primaryCompletion":1851,"completion":2493,"start":2377,"enrollment":3447,"conditions":4540,"interventions":4541},"NCT00953706","Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation",[87],[15],[1478],{"nctId":2952,"briefTitle":2953,"status":119,"phases":4543,"primaryCompletion":2085,"completion":2085,"start":1767,"enrollment":147,"conditions":4544,"interventions":4545},[87],[15],[2936,1478],{"nctId":4547,"briefTitle":4548,"status":119,"phases":4549,"primaryCompletion":1812,"completion":1812,"start":1840,"enrollment":1201,"conditions":4550,"interventions":4551},"NCT01685801","Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function",[87],[15],[1478],{"nctId":4553,"briefTitle":4554,"status":119,"phases":4555,"primaryCompletion":4556,"completion":4556,"start":1967,"enrollment":4557,"conditions":4558,"interventions":4559},"NCT02730208","A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",[87],"2018-07",41,[15],[4560,1478],"Tezacaftor\u002FIvacaftor",{"nctId":4562,"briefTitle":4563,"status":119,"phases":4564,"primaryCompletion":4565,"completion":4565,"start":4566,"enrollment":989,"conditions":4567,"interventions":4568},"NCT02508207","A Phase 2 Study to Evaluate Effects of VX-661\u002FIvacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation",[87],"2017-06","2016-02",[15],[4560,1478],{"nctId":2958,"briefTitle":2959,"status":119,"phases":4570,"primaryCompletion":2961,"completion":2961,"start":2085,"enrollment":2962,"conditions":4571,"interventions":4572},[87],[15],[2936,1478],{"nctId":2110,"briefTitle":2111,"status":119,"phases":4574,"primaryCompletion":1812,"completion":1812,"start":2113,"enrollment":2114,"conditions":4575,"interventions":4576},[87],[15],[1477,1478,2089,2090],{"trials":4578,"activeCount":97},[4579,4585,4592,4599,4603,4607,4614,4618,4624,4632,4638,4642,4646,4654,4658,4664,4672,4680,4684,4693],{"nctId":4580,"briefTitle":4581,"status":403,"phases":4582,"primaryCompletion":334,"completion":334,"start":1949,"enrollment":3145,"conditions":4583,"interventions":4584},"NCT02742519","A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation",[88],[15],[2106],{"nctId":4586,"briefTitle":4587,"status":119,"phases":4588,"primaryCompletion":2085,"completion":2085,"start":1474,"enrollment":4589,"conditions":4590,"interventions":4591},"NCT01705145","Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation",[88],35,[15],[1478],{"nctId":4593,"briefTitle":4594,"status":119,"phases":4595,"primaryCompletion":1890,"completion":1890,"start":1851,"enrollment":4596,"conditions":4597,"interventions":4598},"NCT01117012","Rollover Study of VX-770 in Cystic Fibrosis Subjects",[88],192,[15],[1478],{"nctId":2463,"briefTitle":2464,"status":119,"phases":4600,"primaryCompletion":2466,"completion":2466,"start":2467,"enrollment":2468,"conditions":4601,"interventions":4602},[88],[15],[2471,1478,2472,2473],{"nctId":2490,"briefTitle":2491,"status":119,"phases":4604,"primaryCompletion":1812,"completion":1812,"start":2493,"enrollment":2494,"conditions":4605,"interventions":4606},[88],[2496],[2479,1478],{"nctId":4608,"briefTitle":4609,"status":119,"phases":4610,"primaryCompletion":2840,"completion":2840,"start":1710,"enrollment":4611,"conditions":4612,"interventions":4613},"NCT01946412","Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation",[88],33,[15],[1478],{"nctId":2499,"briefTitle":2500,"status":119,"phases":4615,"primaryCompletion":2502,"completion":2502,"start":1733,"enrollment":2503,"conditions":4616,"interventions":4617},[88],[2505],[2479,1478],{"nctId":4619,"briefTitle":4620,"status":119,"phases":4621,"primaryCompletion":3243,"completion":4109,"start":3936,"enrollment":1142,"conditions":4622,"interventions":4623},"NCT00909727","Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation",[88],[15],[1478],{"nctId":4625,"briefTitle":4626,"status":119,"phases":4627,"primaryCompletion":2502,"completion":2502,"start":4628,"enrollment":4629,"conditions":4630,"interventions":4631},"NCT01707290","Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation",[88],"2013-02",125,[15],[1478],{"nctId":4633,"briefTitle":4634,"status":119,"phases":4635,"primaryCompletion":1733,"completion":1733,"start":1711,"enrollment":1241,"conditions":4636,"interventions":4637},"NCT01614470","Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation",[88],[15],[1478],{"nctId":2120,"briefTitle":2121,"status":119,"phases":4639,"primaryCompletion":335,"completion":335,"start":2123,"enrollment":311,"conditions":4640,"interventions":4641},[88],[15,2125],[1477,1478],{"nctId":2128,"briefTitle":2129,"status":119,"phases":4643,"primaryCompletion":2131,"completion":2131,"start":2101,"enrollment":1832,"conditions":4644,"interventions":4645},[88],[15],[1477,1478],{"nctId":4647,"briefTitle":4648,"status":119,"phases":4649,"primaryCompletion":1948,"completion":1948,"start":4650,"enrollment":4651,"conditions":4652,"interventions":4653},"NCT02412111","A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor",[88],"2015-06",156,[15],[1478,4560],{"nctId":2508,"briefTitle":2491,"status":119,"phases":4655,"primaryCompletion":1812,"completion":1812,"start":2232,"enrollment":2510,"conditions":4656,"interventions":4657},[88],[2496],[2479,1478],{"nctId":4659,"briefTitle":4660,"status":119,"phases":4661,"primaryCompletion":1733,"completion":1733,"start":1711,"enrollment":597,"conditions":4662,"interventions":4663},"NCT01614457","Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)",[88],[15],[1478],{"nctId":4665,"briefTitle":4666,"status":119,"phases":4667,"primaryCompletion":1851,"completion":1776,"start":4668,"enrollment":4669,"conditions":4670,"interventions":4671},"NCT00909532","Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation",[88],"2009-06",167,[15],[1478],{"nctId":4673,"briefTitle":4674,"status":119,"phases":4675,"primaryCompletion":4676,"completion":4676,"start":4677,"enrollment":2728,"conditions":4678,"interventions":4679},"NCT03068312","A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation",[88],"2018-12-18","2017-07-18",[15],[1478],{"nctId":2554,"briefTitle":2555,"status":119,"phases":4681,"primaryCompletion":2557,"completion":2557,"start":499,"enrollment":2558,"conditions":4682,"interventions":4683},[88],[15],[2561,1478],{"nctId":4685,"briefTitle":4686,"status":119,"phases":4687,"primaryCompletion":4688,"completion":4688,"start":4689,"enrollment":4690,"conditions":4691,"interventions":4692},"NCT03150719","A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ\u002FIVA in Orkambi® (Lumacaftor\u002FIvacaftor) -Experienced Subjects With Cystic Fibrosis (CF)",[88],"2018-08-09","2017-05-24",98,[15],[4560,1478],{"nctId":2706,"briefTitle":2707,"status":119,"phases":4694,"primaryCompletion":2709,"completion":2709,"start":2123,"enrollment":2710,"conditions":4695,"interventions":4696},[88],[15],[2695,1478],{"trials":4698,"activeCount":97},[],{"trials":4700,"activeCount":97},[4701],{"nctId":4702,"briefTitle":4703,"status":119,"phases":4704,"primaryCompletion":4705,"completion":4705,"start":1804,"enrollment":4706,"conditions":4707,"interventions":4708},"NCT02445053","Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)",[],"2020-10",75,[15],[2106],{"intervention":1727,"totalTrials":1697,"cells":4710},{"EARLY_PHASE1":4711,"PHASE1":4713,"PHASE2":4735,"PHASE3":4773,"PHASE4":4791,"NA":4797},{"trials":4712,"activeCount":97},[],{"trials":4714,"activeCount":97},[4715,4719,4727,4731],{"nctId":3933,"briefTitle":3934,"status":119,"phases":4716,"primaryCompletion":1085,"completion":1085,"start":3936,"enrollment":849,"conditions":4717,"interventions":4718},[86],[21],[3926,3926,3926,1089],{"nctId":4720,"briefTitle":4721,"status":119,"phases":4722,"primaryCompletion":1795,"completion":1795,"start":4723,"conditions":4724,"interventions":4726},"NCT00509210","Study of Telaprevir in Subjects With Hepatic Impairment",[86],"2007-09",[4725],"Hepatic Insufficiency",[1089],{"nctId":4106,"briefTitle":4107,"status":119,"phases":4728,"primaryCompletion":4109,"start":4110,"enrollment":251,"conditions":4729,"interventions":4730},[86],[21,4112],[1089,4099],{"nctId":1081,"briefTitle":1082,"status":119,"phases":4732,"primaryCompletion":1084,"completion":1084,"start":1085,"enrollment":1086,"conditions":4733,"interventions":4734},[86],[21],[1089,1089,1090,1090,1074,1074],{"trials":4736,"activeCount":97},[4737,4741,4745,4749,4753,4757,4761,4765,4769],{"nctId":1706,"briefTitle":1707,"status":119,"phases":4738,"primaryCompletion":1709,"completion":1710,"start":1711,"enrollment":648,"conditions":4739,"interventions":4740},[87],[1713],[1715,1089,1716],{"nctId":1718,"briefTitle":1719,"status":119,"phases":4742,"primaryCompletion":1721,"completion":1722,"start":1723,"enrollment":1724,"conditions":4743,"interventions":4744},[87],[21],[1727,1696,1728],{"nctId":1730,"briefTitle":1731,"status":403,"phases":4746,"primaryCompletion":1733,"completion":1734,"start":1735,"enrollment":1736,"conditions":4747,"interventions":4748},[87],[1738],[1089,1715,1716,1740,1715],{"nctId":1764,"briefTitle":1765,"status":119,"phases":4750,"primaryCompletion":1473,"completion":1710,"start":1767,"enrollment":1768,"conditions":4751,"interventions":4752},[87],[1713],[1715,1089,1716,1740],{"nctId":1781,"briefTitle":1782,"status":119,"phases":4754,"primaryCompletion":1784,"completion":1784,"start":1785,"enrollment":1786,"conditions":4755,"interventions":4756},[87],[21],[1727,1696,1789],{"nctId":1791,"briefTitle":1792,"status":119,"phases":4758,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1797,"conditions":4759,"interventions":4760},[87],[32],[1696,1728,1727],{"nctId":1801,"briefTitle":1802,"status":403,"phases":4762,"primaryCompletion":1804,"completion":1804,"start":1474,"enrollment":1210,"conditions":4763,"interventions":4764},[86,87],[21],[1727,1807,1696],{"nctId":1809,"briefTitle":1810,"status":403,"phases":4766,"primaryCompletion":1812,"completion":1812,"start":1767,"enrollment":638,"conditions":4767,"interventions":4768},[87],[21],[1727,1696,1815,1816],{"nctId":1818,"briefTitle":1819,"status":119,"phases":4770,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":1823,"conditions":4771,"interventions":4772},[87],[32],[1727,1696,1728],{"trials":4774,"activeCount":97},[4775,4779,4783,4787],{"nctId":1847,"briefTitle":1848,"status":119,"phases":4776,"primaryCompletion":1850,"completion":1851,"start":1852,"enrollment":1853,"conditions":4777,"interventions":4778},[88],[21],[1089,1716,1762],{"nctId":1857,"briefTitle":1858,"status":403,"phases":4780,"primaryCompletion":1775,"completion":1775,"start":1860,"enrollment":1861,"conditions":4781,"interventions":4782},[88],[21],[1727,1696,1815,1864],{"nctId":1866,"briefTitle":1867,"status":403,"phases":4784,"primaryCompletion":1869,"completion":1869,"start":1870,"enrollment":1871,"conditions":4785,"interventions":4786},[88],[1873],[1727,1815,1696],{"nctId":1876,"briefTitle":1877,"status":119,"phases":4788,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":4789,"interventions":4790},[88],[21],[1728,1727,1696],{"trials":4792,"activeCount":97},[4793],{"nctId":1887,"briefTitle":1888,"status":403,"phases":4794,"primaryCompletion":1890,"completion":1890,"start":1891,"enrollment":490,"conditions":4795,"interventions":4796},[89],[21],[1727,1696,1815],{"trials":4798,"activeCount":97},[4799],{"nctId":4800,"briefTitle":4801,"status":119,"phases":4802,"primaryCompletion":1710,"completion":1710,"start":4668,"enrollment":4803,"conditions":4804,"interventions":4805},"NCT00916474","Virology Follow up Study in Subjects Previously Treated With Telaprevir",[],408,[21],[1089],{"intervention":2380,"totalTrials":1182,"cells":4807},{"EARLY_PHASE1":4808,"PHASE1":4810,"PHASE2":4845,"PHASE3":4853,"PHASE4":4859,"NA":4861},{"trials":4809,"activeCount":97},[],{"trials":4811,"activeCount":97},[4812,4819,4823,4829,4833,4837],{"nctId":4813,"briefTitle":4814,"status":119,"phases":4815,"primaryCompletion":1735,"completion":1735,"start":1850,"enrollment":1201,"conditions":4816,"interventions":4818},"NCT01153542","Study of VX-770 on Desipramine",[86],[4817],"In Development for Cystic Fibrosis",[2380,2380],{"nctId":2373,"briefTitle":2374,"status":119,"phases":4820,"primaryCompletion":2376,"completion":2376,"start":2377,"enrollment":1201,"conditions":4821,"interventions":4822},[86],[15],[2366,2380,2381],{"nctId":4824,"briefTitle":4825,"status":119,"phases":4826,"primaryCompletion":3652,"completion":1084,"start":1784,"enrollment":1201,"conditions":4827,"interventions":4828},"NCT01060566","Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770",[86],[15],[2380,2380],{"nctId":3649,"briefTitle":3650,"status":119,"phases":4830,"primaryCompletion":3652,"completion":3652,"start":3653,"enrollment":1201,"conditions":4831,"interventions":4832},[86],[15],[2380,1480],{"nctId":2383,"briefTitle":2384,"status":119,"phases":4834,"primaryCompletion":2386,"completion":2386,"start":2113,"enrollment":123,"conditions":4835,"interventions":4836},[86],[15],[2366,2380,2389,2390],{"nctId":4838,"briefTitle":4839,"status":119,"phases":4840,"primaryCompletion":4841,"completion":4841,"start":4842,"enrollment":1201,"conditions":4843,"interventions":4844},"NCT01208285","Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects",[86],"2010-12","2010-09",[4817],[2380],{"trials":4846,"activeCount":97},[4847],{"nctId":4848,"briefTitle":4849,"status":119,"phases":4850,"primaryCompletion":4628,"completion":4628,"start":2113,"enrollment":93,"conditions":4851,"interventions":4852},"NCT01161537","Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation",[87],[15],[2380],{"trials":4854,"activeCount":97},[4855],{"nctId":2404,"briefTitle":2405,"status":119,"phases":4856,"primaryCompletion":1967,"completion":1967,"start":2407,"enrollment":2214,"conditions":4857,"interventions":4858},[88],[15],[2366,2380],{"trials":4860,"activeCount":97},[],{"trials":4862,"activeCount":97},[4863],{"nctId":4864,"briefTitle":4865,"status":728,"phases":4866,"conditions":4867,"interventions":4868},"NCT01381289","VX-770 Expanded Access Program",[],[15],[2380],{"intervention":4560,"totalTrials":12,"cells":4870},{"EARLY_PHASE1":4871,"PHASE1":4873,"PHASE2":4875,"PHASE3":4885,"PHASE4":4895,"NA":4897},{"trials":4872,"activeCount":97},[],{"trials":4874,"activeCount":97},[],{"trials":4876,"activeCount":97},[4877,4881],{"nctId":4553,"briefTitle":4554,"status":119,"phases":4878,"primaryCompletion":4556,"completion":4556,"start":1967,"enrollment":4557,"conditions":4879,"interventions":4880},[87],[15],[4560,1478],{"nctId":4562,"briefTitle":4563,"status":119,"phases":4882,"primaryCompletion":4565,"completion":4565,"start":4566,"enrollment":989,"conditions":4883,"interventions":4884},[87],[15],[4560,1478],{"trials":4886,"activeCount":97},[4887,4891],{"nctId":4647,"briefTitle":4648,"status":119,"phases":4888,"primaryCompletion":1948,"completion":1948,"start":4650,"enrollment":4651,"conditions":4889,"interventions":4890},[88],[15],[1478,4560],{"nctId":4685,"briefTitle":4686,"status":119,"phases":4892,"primaryCompletion":4688,"completion":4688,"start":4689,"enrollment":4690,"conditions":4893,"interventions":4894},[88],[15],[4560,1478],{"trials":4896,"activeCount":97},[],{"trials":4898,"activeCount":97},[4899],{"nctId":4900,"briefTitle":4901,"status":728,"phases":4902,"conditions":4903,"interventions":4904},"NCT03278314","Tezacaftor\u002FIvacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis",[],[15],[4905],"tezacaftor\u002Fivacaftor",{"intervention":4907,"totalTrials":137,"cells":4908},"AVN944",{"EARLY_PHASE1":4909,"PHASE1":4911,"PHASE2":4913,"PHASE3":4922,"PHASE4":4924,"NA":4926},{"trials":4910,"activeCount":97},[],{"trials":4912,"activeCount":97},[],{"trials":4914,"activeCount":97},[4915],{"nctId":4916,"briefTitle":4917,"status":403,"phases":4918,"primaryCompletion":2376,"completion":2376,"start":3370,"enrollment":2102,"conditions":4919,"interventions":4921},"NCT00493441","AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer",[87],[4920],"Pancreatic Cancer",[4907],{"trials":4923,"activeCount":97},[],{"trials":4925,"activeCount":97},[],{"trials":4927,"activeCount":97},[4928],{"nctId":4929,"briefTitle":4930,"status":2624,"phases":4931,"primaryCompletion":3652,"completion":3652,"start":1722,"enrollment":97,"conditions":4932,"interventions":4934},"NCT00923728","A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors",[90],[4933],"Refractory Solid Tumors",[4907],{"intervention":4936,"totalTrials":235,"cells":4937},"Ivacaftor Exposed",{"EARLY_PHASE1":4938,"PHASE1":4940,"PHASE2":4942,"PHASE3":4944,"PHASE4":4946,"NA":4948},{"trials":4939,"activeCount":97},[],{"trials":4941,"activeCount":97},[],{"trials":4943,"activeCount":97},[],{"trials":4945,"activeCount":97},[],{"trials":4947,"activeCount":97},[],{"trials":4949,"activeCount":97},[4950],{"nctId":4951,"briefTitle":4952,"status":119,"phases":4953,"primaryCompletion":1949,"completion":1949,"start":2493,"enrollment":4954,"conditions":4955,"interventions":4956},"NCT01863238","An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis",[],95,[15],[4936]]